

CURRICULUM VITAE

Lisa M. Coussens, Ph.D.

Professor and Chair, Department of Cell & Developmental Biology
Hildegard Lamfrom Chair in Basic Research
Associate Director for Basic Science, Knight Cancer Institute

Oregon Health & Sciences University
Richard Jones Hall, Room 5508
3181 SW Sam Jackson Park road
Portland, OR 97239-3098

Voice: (503) 494-7811
Fax: (503) 494-4253
Email: cousseni@ohsu.edu

I. EDUCATION:

1976 - 1980	San Francisco State University	B.A.	Biology
1988 - 1993	University of California, Los Angeles	Ph.D.	Biological Chemistry
1993 - 1997	University of California, San Francisco	Post-Doctoral Fellow	Cancer Biology

II. PRINCIPAL POSITIONS HELD:

1981 - 1988	Genentech, Inc., South San Francisco	Research Associate	Molec. & Devel. Biology
1997 - 1999	Univ. of California, San Francisco	Assistant Research Biochemist	Hormone Research Inst.
1999 - 2004	Univ. of California, San Francisco	Assistant Professor, In Residence	Cancer Research Inst. & Dept of Pathology
2004 - 2006	Univ. of California, San Francisco	Associate Professor, In Residence	Cancer Research Inst. & Dept. of Pathology
2006 - 2007	Univ. of California, San Francisco	Associate Professor	Dept. of Pathology & Cancer Research Inst.
2007 - 2012	Univ. of California, San Francisco	Professor	Dept. of Pathology & Cancer Research Inst.
2012 - present	Univ. of California, San Francisco	Adjunct Professor	Dept. of Pathology
2011 - present	Oregon Health & Science University	Professor and Chair	Cell & Developmental Biology
2011 - present	Oregon Health & Science University	Associate Director for Basic Research	Knight Cancer Institute

OTHER POSITIONS HELD CONCURRENTLY:

1989 - 1992	Whittier College, Whittier, CA	Lecturer	Biology Dept
1992	Genentech, Inc., South San Francisco	Scientific Consultant	Dept. of Legal Affairs
2000-2012	Helen Diller Family Comprehensive Cancer Center, UCSF	Co-Director	Mouse Pathology Core
2007-2009	<i>CANCER RESEARCH</i>	Senior and Deputy Editor	<i>Tumor Microenvironment Section</i>
2009-2012	Helen Diller Family Comprehensive Cancer Center, UCSF	Co-Leader	<i>Program in Cancer Immunity & Microenvironment</i>
2009-2012	<i>CANCER RESEARCH</i>	Deputy Editor	<i>Breaking Advances</i>

III. HONORS AND AWARDS:

1985	Recognition Award	Genentech, Inc.,
1986	Recognition Award	Genentech, Inc.,
1988	Recognition Award	Genentech, Inc.
2000 - 02	Hellman Family Award For Early Career Faculty	Univ. of Calif., San Francisco
2000 - 01	V Foundation Scholar	The V Foundation for Cancer Research
2000 - 03	Edward Mallinckrodt, Jr. Fndt. Award for Medical Research	Edward Mallinckrodt, Jr. Fndt.

2002	Gertrude B. Elion Cancer Research Award	American Association for Cancer Research
2006 - 11	Era of Hope Scholar Award	Dept. of Defense, Breast Cancer Research Program
2011 - 16	Era of Hope Scholar Expansion Award	Dept. of Defense, Breast Cancer Research Program
2011 - 16	KOMEN Promise Award	Susan G Komen For the Cure Foundation
2012	AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship	American Association for Cancer Research – Women in Cancer Research
2012	Mildred Scheel Memorial Lectureship (Inaugural)	German Cancer Aid and Deutsches Krebsforschungszentrum
2013	American Cancer Society/SSO Basic Science Lecture	Society for Surgical Oncology

IV. PROFESSIONAL ACTIVITIES

External Scientific Advisory Board Membership

2007 - 2013	Member	(P30) Masonic Cancer Center, University of Minnesota, Minneapolis MN, USA
2007 – 2011	Member	(U54) <i>Aging, Tumor Microenvironment and Prostate Cancer</i> ; PI: S. Plymate; Univ. of Washington, Seattle WA USA
2007 – 2011	Member	(U54), <i>Novel Methods for Detection Cell Interactions in the Tumor Microenvironment</i> ; P.I. J Condeelis. Albert Einstein College of Medicine of Yeshiva University, New York, NY USA
2009 - 2013	Member	(P01), <i>Neuroblastoma</i> ; P.I. R Seeger, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA USA
2009 - present	Member	(P01) <i>Motility and Invasion</i> , PI: J Condeelis; Albert Einstein College of Medicine, NY, NY USA
2012 - present	Member	(P30) Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis IN, USA
2012 - present	Member	(P30) Koch Institute for Integrated Cancer Research, Massachusetts Inst. of Tech. Cambridge, MA USA
2013 - present	Member	Biodesign Institute at Arizona State University, Tempe, AZ USA
2013	Member	LabEx, Paris France
2013 - present	Member	Gilead Sciences, Inc., Foster City CA, USA
2013 - present	Member	Cancer Research Institute (CRI)
2013 - present	Member	The V Foundation for Cancer Research

Scientific Review Board membership

2011	Member	Starr Cancer Consortium
------	--------	-------------------------

Local, National and International Meetings Organized:

2005	Keystone Symposia, <i>Inflammation and Cancer</i> , Co-organizer with Dr. Ray DuBois (Vanderbilt Univ, TN), Breckinridge, CO, USA
2006	5 th Annual Timberline Symp. on Epithelial Cell Biology, ' <i>Intrinsic and Microenvironmental Regulation of Epithelial Cancer</i> ', Co-Organizer with Dr. Harold Moses (Vanderbilt University, TN, USA), Timberline, OR, USA
2006	Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Annual Symposium, ' <i>Inflammation & Cancer: Bench to Bedside</i> '.
2007	Keystone Symposia, <i>Inflammation and Cancer</i> , Co-Organizer with Drs. Fran Balkwill (Cancer Research UK) and Glenn Dranoff (Beth Israel Cancer Center, Harvard, MA); Santa Fe, New Mexico, USA
2008	AACR Special Conference: <i>Inflammation and Cancer</i> , Co-organizer with Drs. Michael Karin (UCSD) and Larry Marnett (Vanderbilt UNiv.). Oahu, Hawaii, USA.

- 2008 International Society for Biological Therapy of Cancer (ISBTc), *2008 Workshop on Inflammation in Cancer Development*, Co-Organizer with Drs. Michael Karin, (UCSD), Steven Dubinett (UCLA), and George Weiner (WU); San Diego CA USA
- 2010 Co-Organizer (with Dr. Lewis Lanier), UCSF HDFCCC Program in *Cancer Immunity and Microenvironment* Symposium
- 2011 AACR *Special Conference: Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, Co-Organizer with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL). Miami, FL USA
- 2014 Keystone Symposia, *Immune Evolution in Cancer*, Co-Organizer with Drs. Suzanne Ostrand-Rosenberg (Univ. Maryland) and Olja Finn (Univ. of Pittsburgh). Whistler, British Columbia, CANADA
- 2014 *3rd International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets*, Mykonos, Greece. Co-organizer with Drs Amato Giacci (Stanford Univ) and Alexia Ileana-Zaromytidou (Nature Cell Biology).

SERVICE TO PROFESSIONAL SOCIETIES

American Association for Cancer Research (Member, 2013 - present)

- 2003 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) Cellular, Molecular and Tumor Biology Subcommittee, AACR Program Committee for *94th Annual Meeting*.
- 2003 Chair and organizer, Educational Session (Proteases: Successes and Failures): *94th Annual Meeting*, Washington D.C., USA
- 2003 Minisymposium Co-chair (Inflammatory Mediators & Cancer): *94th Annual Meeting*, Washington D.C., USA
- 2004 - 2006 Member, Grants Committee
- 2005 Minisymposium Co-Chair (Inflammation, Microenvironment and Tumor Progression): *96th Annual Meeting*, Anaheim, CA USA
- 2005 Session Chair (Inflammation): *AACR Special Conference: Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA
- 2006 Subsection Co-chair (Tumor Progression, Invasion and Metastasis) of the Tumor Biology Subcommittee, AACR Program Committee for *97th Annual meeting*
- 2006 Minisymposium Co-Chair (Inflammation and Cancer): *97th Annual Meeting*, Washington DC, USA
- 2006 Co-Chairperson, Program Committee: *6th Annual Frontiers in Cancer Prevention Research Conference*, December 5-8, 2007, Philadelphia, PA USA.
- 2006 - 2010 Steering Committee Member: AACR Tumor Microenvironment Working Group (TME/AACR).
- 2007 Organizer, Education session (Inflammation and Cancer), *98th Annual Meeting*, Los Angeles, USA
- 2007 Minisymposium Co-Chair (Tumor Microenvironment): *98th Annual Meeting*, Los Angeles, CA USA
- 2007 Co-Chairperson, Program Committee: *2008 99th Annual Meeting of the AACR*. April 12-16, 2008, San Diego, CA. USA
- 2008 Program Committee Member, Tumor Microenvironment Subcommittee for *99th Annual Meeting of the AACR*. April 12-16, 2008, San Diego, CA. USA
- 2007 - 2010 Member, AACR Special Conferences Committee
- 2008 Co-Organizer Special Conference: *Inflammation and Cancer*, with Drs. Michael Karin and Larry Marnett. Oahu, Hawaii, USA.
- 2008 - 2011 3-56Member, Board of Directors (elected)
- 2009 Member, 2009 Education Committee, 2009 100th AACR Annual Meeting, Denver, CO. USA
- 2009 Organizer and Chair: *Inflammation and Cancer: Novel Mechanisms Regulating Protumor Immunity* Major Symposium, 2009 100th AACR Annual Meeting, Denver, CO. USA
- 2009 Organizer and Chair: Education Session, *Aspects of the Tumor Microenvironment that Regulate Solid Tumor Development*, 2009 100th AACR Annual Meeting, Denver, CO. USA
- 2010 Co-Chairperson, Program Committee: *2010 101st Annual Meeting of the AACR*, April 17-21, 2010, Washington, DC USA
- 2009 Member, Scientific Review Committee for *Stand Up to Cancer Innovative Research Grants*

- 2009 - 2010 Member, Selection Committee: *2010 Pezcoller Foundation-AACR International Award for Cancer Research*
- 2010 - 2011 Council Member, *Women in Cancer Research Council* (elected)
- 2010 Co-Chair, Minisymposium '*The Tumor Microenvironment and Therapeutic Strategies*' 2010 101st Annual Meeting of the AACR, April 17-21, 2010, Washington, DC USA
- 2010 - 2011 Member, Selection Committee: 2010-2011 AACR Award for Lifetime Achievement in Cancer Research
- 2011 Co-Chair, Minisymposium '*Tumor Microenvironments*' 2011 102st Annual Meeting of the AACR, April 3-6, 2010, Orlando, FL USA
- 2011 Co-Organizer with Drs. Yves DeClerck (USC, Children's Hospital) and Melody Swartz (EPFL); AACR Special Conference: *Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, November 2011, Orlando FL USA
- 2012 Co-Chairperson, Program Committee: 2012 103rd Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Chair, Plenary session: "Tumor Heterogeneity: Challenges and Therapeutic Opportunities" 2012 103rd Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Chair, Education session: "Tumor Microenvironment" 2012 103rd Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Chair, 2012 Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research Scientific Review Committee, Dr. Judith Varner, recipient.
- 2012 Speaker, 2012 AACR Meet the Research Pioneer, 2012 103rd Annual Meeting of the AACR, April 3-6, 2010, Chicago, IL USA
- 2012 Organizing Committee for 9th AACR-Japanese Cancer Association International Conference, February 21-25, 2013, Maui, Hawaii.
- 2012 Cancer Immunology (CImm) Chairperson-elect Nominating Committee 2013-2014.
- 2013-present Senior Editor, *Cancer Immunology Research*
- 2013 Member, 2014 AACR Princess Takamatsu Memorial Lectureship Award Committee
- 2013-2015 Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee
- 2014 Chair, Education session: *Phenotyping and Function of Solid Tumor Stroma*" 2014 105th Annual Meeting of the AACR, April 2014, San Diego, CA USA
- 2014 Personalized Career Discussions, Associate Member Council, 2014 105th Annual Meeting of the AACR, April 2014, San Diego, CA USA
- 2015 Program Committee, Second AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy, San Diego, CA USA.
- 2014 Member Selection Committee, 2014-2015 Pezcoller Foundation-AACR International Award for Cancer Research Committee.

American Society for Cell Biology (Member, 2001 – 2008)

- 2000 American Society for Cell Biology, photo credits in '*Exploring the Cell*' Ed. W. Wells
- 2001 Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee, 40th Annual Meeting, Washington, DC, USA
- 2001 Co-chair and Co-organizer, Mini-symposium (Microenvironment/Extracellular Matrix in Development and Disease): 40th Annual Meeting, Washington, DC, USA
- 2003 Table Leader, Career Discussion Lunch, Women in Cell Biology and Education Committee of the ASCB, 42nd Annual Meeting, San Francisco, CA, USA
- 2006 Co-Chair Minisymposium (Cancer Mechanisms): 46th Annual Meeting, San Diego CA, USA

American Association for Advancement of Science (Member, 2011 – present)

- 2014-2017 Elected, member of the Electorate Nominating Committee (ENC) of the Section on Medical Sciences

International Proteolysis Society (Member, 2004 – 2009)

- 2007 Member, International Scientific Advisory Committee, 5th General Meeting of the International Proteolysis Society, Rion-Patras, GREECE.
- 2011 Member, Organizing Committee, 9th General Meeting of the International Proteolysis Society, San

Diego CA, USA

American Cancer Society

- 1999 14th Annual Excalibur Round Table, San Francisco, CA, USA
 2000 San Mateo County Annual Volunteer Meeting, San Mateo, CA, USA

International Society for Preventive Oncology

- 2002 Session Chair (Chemoprevention): 6th Annual Meeting, Pasteur Institute, Paris, France.
 2002 Poster Judge (Chemoprevention): 6th Annual Meeting, Pasteur Institute, Paris, France.

International Society for Biological Therapy of Cancer (iSBTc)

- 2008 Co-Organizer (with Drs. Michael Karin, Steven Dubinett, George Weiner), 2008 Workshop on Inflammation in Cancer Development, San Diego CA, USA

Society for Immunotherapy of Cancer (SITC)

- 2013 SITC Annual Meeting, Session Co-Organizer and Co-Chair (with Georgio Trinchieri, NCI), SITC Tumor Microenvironment and Innate Cells Recognition, Bar Harbor, MA USA

Other Professional Society Memberships

- 2000 - 2009 American Society for Matrix Biology
 2004 - present American Society for Investigative Pathology

Service to Professional Publications:

- 2003 - 2005 Associate Editor, **Cancer Research**
 2005 – 2007 Editorial Board, **Carcinogenesis**
 2004 – 2007 Senior Editor, **Cancer Research** (Cell, Tumor and Stem Cell Biology Section)
 2007 – 2009 Senior Editor, **Cancer Research** (Tumor Microenvironment Section)
 2007 – 2009 Deputy Editor, **Cancer Research**
 2007 Guest Editor, PNAS Editorial Board
 2008 Guest Editor (with Tyler Jacks), *Current Opinion in Genetics & Development*
 2008 – 2010 Editorial Board, **Cancer Microenvironment**
 2009 – 2012 Deputy Editor for Breaking Advances, **Cancer Research**
 2012 – present Editorial Board, **Cancer Cell**
 2012 – present Senior Editor, **Cancer Immunology Research**
 2013 – present Editorial Board, **Cancer Immunology, Immunotherapy**
 2013 – present Guest editor, Editorial Committee, **Annual Reviews of Pathology**

Ad hoc peer-reviewed manuscript reviewing

- 1994 Oncogene;
 1995 Am J Pathology; Matrix Biology; J Cell Biology
 1999 Am J Pathology; Cancer Letters; Nature Medicine; Nature; PNAS; Cell Motility & the Cytoskeleton; Cancer Research
 2000 Am J Pathology; Cancer Research; Genes & Development; Int. J Cancer
 2001 J Cell Biology; Int. J of Cancer; EMBO; Neoplasia; Cancer Research
 2002 Cancer Research; Am J Pathology; Int. J Cancer; Biological Chemistry; Cancer Cell; Cancer Letters
 2003 PNAS; Cancer Research; Int. J of Cancer; J Molecular Medicine; Biological Chemistry; Science; Cancer Cell; Nature Medicine; J Leukocyte Biology; Neoplasia; Am J Pathology
 2004 Lancet; Cancer Cell; Cancer Research; American J Pathology; J Cell Biology; Nature Reviews Immunology; Nature Reviews Cancer; PNAS; J Biological Chemistry; Nature; J Exp Med; Int J Cancer
 2005 Nature Medicine, Cancer Cell, Cancer Research; Am J Pathology; Cell; Nature; Nature Reviews Immunology; Nature Reviews Cancer; Carcinogenesis
 2006 Nature Reviews Cancer; Nature; Nature Medicine; Cell; Cancer Research; Clinical Cancer Research; J Exp Med; Cancer Cell: Am J Pathology; J Cell Biology
 2007 Cell; Nature; PNAS: J Cell Biology; Cancer Research; J Exp Med; Breast Cancer Research

- 2008 Cancer Cell; PNAS; J Immunology; Nature; J Exp Med; Trends in Genetics; Current Opinions in Investigational Drugs
- 2009 Cancer Cell; Cell; Nature; J Exp Med; J Clin Invest, Cancer Research; Int J Cancer; Oncogene, J Immunology
- 2010 Nature, J Exp Med, Nature Medicine, J Invest Dermatology, Cell, Cancer Cell, J Clinical Onc; PNAS; J Clin Invest; Cancer Research; Dis Mech Models; Cancer Immuno Immunother;
- 2011 Nature; Nature Medicine; Cancer Research; Cancer Cell; J Clin Invest; Breast Cancer Research; PlosOne, PNAS; Oncogene; J Exp Med; Oncogene;
- 2012 PNAS; Can Res; Oncogene; Trends in Immunology; Nature; Clin Can Res; J Exp Med; Cancer Discovery; Immunity; J Cell Physio; JoVE; Immunity; J Clin Invest; BBA - Molecular Basis of Disease; Can Res; EMBO; Genes & Dev.; Nature Cell Biol.; TREIMM; Blood; Nature Medicine; Science Trans Med;
- 2013 Cancer Discovery; Cell; Genes & Dev; Nature; Cancer Research, J Translational Medicine; J Exp Res, Nat Med; Frontiers in GI Science; Science Transl Med; Nat Comms; Lung Cancer;
- 2014 Cancer Cell; Cell; Nature Med; PNAS; J Exp Med; Can Res; Immunity; Can Disc; Br Can Res; Science Transl Med;

Government Service

2003 - 2006	National Institutes of Health, Center for Scientific Review	Ad hoc reviewer (10/2003; 02/2005; 10/2005; 06/2006), Tumor Progression & Metastasis (TPM) Study Section, Oncological Sciences Review group
2003	Division of Cancer Biology, National Cancer Institute: <i>Microenvironment Think Tank</i>	Participant and <i>Reporter</i>
2003	Division Cancer Etiology, National Cancer Institute: <i>Validation of A Causal Relationship: Criteria to Establish Etiology Think Tank</i>	Invited speaker and Participant
2004	National Institutes of Health, National Cancer Institute	Subcommittee C (05/2004) – Basic & Preclinical NCI Initial Review Group, NCI-C RPRB (T2) Angiogenesis
2005	National Institutes of Health, National Cancer Institute	Subcommittee D (02/2005) – Clinical Studies NCI Initial Review Group, NCI-D RPRB Tumor Pathology
2005	National Institutes of Health, Center for Scientific Review-Oncology	Special Emphasis Panel (SEP); ZRG1 ONC (03) M, Developmental Therapeutics
2010	National Institutes of Health, Center for Scientific Review-Neuroscience	Special Emphasis Panel (SEP)/Scientific Review Group 2010/05 ZNS1 SRB-R (47)
2010	National Institutes of Health, Center for Scientific Review-Neuroscience	Special Emphasis Panel (SEP)/Scientific Review Group 2011/01 ZRG1 DTCS-A (81)
2010 - 2011	Department of Defense (DOD), Breast Cancer Research Program (BCRP)	6 th Era of Hope conference Technical Planning Committee (TPC)
2011	National Institutes of Health, Center for Scientific Review	Ad hoc reviewer (06/2011), Cancer Immunotherapy & Immunology (CII) Study Section, Oncology 2 - Translational Clinical IRG (OTC) Division of Translational and Clinical Sciences

Other Professional Ad Hoc Service

1999	Arkansas Science & Technology Authority	Ad hoc Grant Review
2000	McGraw-Hill, 'Biology' 6 th edition, Ed. P.H. Raven and G.B. Johnson	Ad hoc Review, Chapters 17 and 18
2001	Department of Veterans Affairs	Ad hoc Grant Review, Oncology Review Board
2001	Research Grants Council of Hong Kong	Ad hoc Grant Review
2003	Danish Cancer Society, DENMARK	Ad hoc Grant Review
2004	Division of Gastroenterology and Digestive	PO1 External Advisory Panel

	Disease Research Center, Vanderbilt University, Nashville TN, USA	
2004	Cancer Research Ireland, Irish Cancer Society	Ad hoc grant review
2004	Dutch Cancer Society	Ad hoc grant review
2004	Vanderbilt University, Nashville TN, USA; SPORE in GI Cancer	Ad hoc reviewer for SPORE Developmental Research Program
2006	Keystone Symposia Cancer Study Group for 2009 programming	Study group member
2009	GlaxoSmith Kline	Member, Tykerb Post-ASCO KOL Advisory Board
2009 - 2010	Cancer Prevention and Research Institute of Texas (CPRIT)	Member, Scientific Review Committee; Basic Cancer Biology Review Committee
2011	Starr Cancer Consortium Scientific Review Board	Member, Scientific Review Committee
2013	AIRC – Italian Association for Cancer Research	Site visit review committee member, Istituto Clinico Humanitas - Centro Congressi

IV. UNIVERSITY AND PUBLIC SERVICE

University Service

Oregon Health and Sciences University

- 2012 – present Faculty member, Graduate program in Molecular & Cellular Biosciences
- 2012 – present Faculty member, OHSU Knight Cancer Institute, Program in Cancer Biology
- 2012-2013 Member, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology (Successful recruitments of **Evan Lind, Jeffrey Nolze**)
- 2013 Member, Search Committee, Depts of Cell & Developmental Biology, Molecular and Microbial Immunology, Biomedical Engineering, Knight Cancer Institute (Successful recruitments of **Amanda Lund**)
- 2013 Co-Chair (with Chris Amling), Search Committee, Dept. of Cell and Developmental Biology, Dept of Urology and Knight Cancer Institute (Successful recruitment of **Kunyoo Shin**)
- 2013 Chair, Search Committee, Dept. of Cell and Developmental Biology and Knight Cancer Institute (Successful recruitments of **Sudarshan Anand, Pepper Schedin, and Sara Courtneidge**)
- 2012-present Co-Chair (with Kevin Billingsley), Search Committee, Dept of Medicine. Division of Hematology & Oncology and Knight Cancer Institute
- 2012 Chair, V Foundation Scholar nomination committee
- 2012-present Member, Executive Steering Committee for PhD Graduate Programs
- 2013 -present Member, Center for Women's Health, Internal Advisory Committee
- 2013 -present Member, OHSU Research Council
- 2013 – present Member, Oregon Clinical and Translational Research Institute (OCTRI) Research review committee
- 2013 Member, Search Committee for Chair, Dept of Medicine.
- 2014 -present Member, Research Roadmap Task Force 1
- 2014 Table Discussion Leader, 2nd Annual BIRCWH Northwest Women's Health Research and Leadership Conference, Portland OR

University of California; System wide

- 1992-1993 Graduate Student Representative, Dept. of Biological Chemistry Faculty Council, UCLA
- 2004 *ad hoc* Member External Advisory Panel; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles CA, USA
- 2009 Member, Site Visit Programmatic Review Group, Department of Pathology & Laboratory Medicine, UCLA School of Medicine. Graduate Council of the UCLA Academic Senate.

University of California, San Francisco; CAMPUS-WIDE

- 1997 Presentation, Donor Seminar, UCSF Development Office

1998	Presentation, Donor Seminar, UCSF Development Office
1999 – 2012	Member, Graduate Program in BioMedical Sciences (BMS)
2000 - 2012	Member, Graduate Program in Biological Sciences (PIBS)
2000 – 2004	Member, Steering Committee, Ovarian Cancer Program Project Grant
2000 – 2005	Member, Scholarships and Awards Committee, Academic Senate, School of Medicine
2001 – 2012	Member, BioMedical Sciences Graduate Program (BMS) Executive Committee
2002 – 2004	Member, Medical Scientist Training Program Executive Committee
2004 - 2006	Member, Search Committee, Director of Molecular Imaging, Dept. of Radiology, Committee Chair: Ron Arenson, M.D. no successful recruitment
2004 – 2006	Member, BioMedical Sciences Graduate Program (BMS); Admissions Committee
2004	Organizer, BioMedical Sciences Graduate Program Retreat, Granlibakken, N. Lake Tahoe, CA USA
2004 – 2012	Member, Graduate program in Immunology
2005 - 2006	Member, Tissue Engineering Ladder-rank Faculty Search Committee, Dept. of Surgery. Committee Chair: Nancy Boudreau, Ph.D. Successful recruitment of Valerie Weaver, Ph.D.
2005 - 2009	Member, Ethel and Jane Sokolow Memorial Cancer Endowment Lectureship Committee.
2006	Member, Cancer Faculty Search Committee, Anatomy Dept., Committee Chair: Zena Werb, Ph.D. Successful recruitment of Jeroen Roose, Ph.D.
2006	Member, Faculty Advisory Committee for 2007 Journalist Seminar on <i>Inflammation and Disease</i> . Sponsored by Associate Vice Chancellor Barbara J. French
2007	Member, committee to select recipient of Dean's Postdoctoral Prize Lecture.
2007	Member, Faculty Search Committee for Restorative Neurosurgery and Stem Cell Neurobiology, VA Medical Center/UCSF NeuroSurgery. Committee Chair: Linda Noble, Ph.D.; Status: not filled.
2009	Member, Committee to choose 1 st Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology, School of Medicine, UCSF. Recipient: Thierry Jahon, M.D.
2010	Member, 2010 Selection Committee for the Hellman Family Early-Career Faculty Awards.

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

1999-2012	Member, Helen Diller Family Comprehensive Cancer Center
1999	Member, Cancer Center Research Building Space Review Policy Committee
1999 – 2002	Member, Mt Zion Animal Barrier Facility Committee
1999 – 2005	Member, Cancer Center Friday Seminar Series Committee
2000	Organizer and Chair, MZ Cancer Center Research Building Annual Retreat
2001 – 2012	Co-Director, Mouse Pathology Core
2001	Member, 'Star Performance Award' selection committee
2001	Presentation, Evelyn Herman Reception, UCSF Development Office
2001 – 2002	Member, Cancer Center Research Building, 'Cancer Center Faculty Working Group'
2001 – 2006	Member, Mouse Models of Human Cancer Working Group
2002 – 2003	Member, UCSF Mt Zion campus, Animal Protocol Review Committee
2002	Member, ACS IRG grant review committee
2002 – 2006	Steering Committee Member, Mouse Models of Human Cancer
2003	Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2003 – 2009	Chair, UCSF Mt Zion Campus Animal Protocol Review Committee
2003	Member, Search Committee: Associate Director for Administration, UCSF Comprehensive Cancer Center (Erica Weber, recruited)
2004	Member, Review Committee, UCSF Comprehensive Cancer Center Stewart Trust Award
2006	Co-Organizer, UCSF CCC Annual Symposium, ' <i>Inflammation & Cancer: Bench to Bedside</i> '.
2008	Chair, Committee to nominate Postdoctoral scholar for AACR 2008 Annual Meeting, Inaugural "Future Leaders, New Directions" Special Symposium. Nominee: Laura Soucek, Ph.D. (awarded)
2009 – 2012	Co-Leader, Program in <i>Cancer Immunity and Microenvironment</i>

University of California, San Francisco, Cancer Research Institute

2001 – 2002 Member, Cancer Research Institute Membership Subcommittee

University of California, San Francisco, Department of Pathology

2003 Member, Committee to recommend faculty for the *Robert E. Smith Endowed Chair in Experimental Pathology*

2004 Member, Search Committee, Ladder rank faculty, Physician-Scientist, Anatomic Pathology. Successful recruitment of Jay Debnath, M.D., Ph.D.

2007 Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Pathology and Neuropathology. Committee Chair: Michael D Prados, M.D.; Status: open.

2008 Member, Search Committee, Ladder-rank faculty, Physician-Scientist, Experimental Pathology. Committee Chair: Benedict Yen, M.D.; Status: open

2009-2011 Member, Academic Merit and Promotions Committee; Pathology Dept.

University (other)

2002 Guest Instructor, Graduate Oncology, University of Missouri, Columbia, Missouri USA

2003 Guest Instructor, Cancer Biology, Stanford University, Stanford, CA USA

2004 Guest Instructor, Immunology, Stanford University, Stanford, CA USA

2008 Guest Instructor, *Exploring the Tumor microenvironment*, Postgraduate course, ISREC, Lausanne University's Biochemistry and Biology Departments, and the Lausanne Branch of the Ludwig Institute, Lausanne Switzerland. Course Organizers, Ivan Stamenkovic and Michel Aguet

Public Service:

1990 Lecturer, Science Academy Of Whittier, Summer Institute. Whittier College, Whittier, CA

1991 Organizer and Lecturer, Science Academy Of Whittier, Summer Institute. Whittier College, Whittier, CA.

1993 Lecturer, Joslyn Community Center. Claremont, CA.

1994 Provided elementary educators with science-related supplies (photos, slides, fixed tissue samples).

1995 Co-Coordinator Hormone Research Institute, 'Take Our Daughters To Work Day', Univ. of Calif., San Francisco

2002 Photo credits and interviewed for '*Misdiagnosis: Failure of Promising Cancer Treatment Starts Soul Searching by Researchers & Drug Companies*', in: *San Francisco Chronicle*, May 12, 2002.

2003 Interviewed for article '*Body's First Defense May Be Root of Diseases*', in: *The Washington Post*, February 20, 2003

2003 Interviewed for article '*The Body on Fire*', in: U.S. News & World Report, October 20, 2003

2004 Interviewed for comments in: *Science News*, '*Early Warming: Inflammatory protein tied to colon cancer risk*' February 7, 2004, Vol 165.

2004 Interviewed for article '*The Fires Within*', in: *TIME Magazine*, February 23, 2004

2004 Interviewed for comments on AACR Annual Meeting in: *Oncology Times*, '*Exercise Reduces Inflammatory Response, May also Reduce Cancer Risk*', Robert H Carlson, 26(11):33-34, June 10, 2004

2004 Interviewed for article '*Inflammation and Cancer: The Link Grows Stronger*', in: *Science*, 306, 966-968 (2004)

2005 Interviewed for article '*Quieting a Body's Defenses*', in: *Newsweek*, Special Edition, Summer 2005

2006 Interviewed for "Expert Commentary" by *BreastLink.org*, on article "Association Between Circulating White Blood Cell Count and Cancer Mortality." *Archives of Internal Medicine*, January 23, 2006; 166:188-194.
http://www.breastlink.org/index.php?module=announce&ANN_user_op=view&ANN_id=208

2007 UCSF Research Perspectives 2007 – Inflammation as Cause and Consequences of Disease, Media Event for Journalists, September 27, 2007, UCSF Mission Bay Campus

2007 On-Air radio interview by Dave Iversen, KQED *FORUM*, September 28, 2007 San Francisco CA USA

2012 Delta Kappa Gamma Society International, Winter Keynote Lecture; January 23, 2012, Fairfield, CA USA

2012 Continuing Education Webinar, Project LEAD, Center for NBCC Advocacy Training, National Breast Cancer Coalition

2014 **KEYNOTE SPEAKER**; 2014 Breast Cancer Issues Conferences, Susan G. Komen, Oregon and Washington. Portland OR USA

2014 **KEYNOTE SPEAKER**; 2014 Betty Hise Foundation for Cancer Research Annual Convention. Clackamas, OR

V. TEACHING AND MENTORING

Formal Scheduled Classes for OHSU Students:

Qtr	Academic Yr	Course No. & Title	Teaching Contribution	Units	Class Size
S	2011/2012	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	20
S	2012/2013	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	20
S	2012/2013	CONJ665; <i>Development, Differentiation and Cancer</i>	Co-Director, Lecturer	3	10
S	2013/2014	HIP505; Human Investigations Program	Lecture: <i>Team Science: Secrets to success in interdisciplinary research across the lifespan</i>	2	13
S	2013/2014	CELL616; <i>Advanced Topics in Cancer Biology</i>	Lecture: <i>Tumor Microenvironment</i>	3	12
S	2013/2014	CONJ665; <i>Development, Differentiation and Cancer</i>	Co-Director, Lecturer	3	12

Formal Scheduled Classes for UCSF Students:

Qtr	Academic Yr	Course No. & Title	Teaching Contribution	Units	Class Size
W	1997/98	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
W	1998/99	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
W	1999/00	IDS 100; Histology Laboratory	<i>Neoplastic Skin Histopathology</i> ; Laboratory lecture & instruction	10	150
S	1999/00	BMS 297A; Molecular Biology & Pathology of Neoplasia	<i>Animal Models of Cancer Laboratory</i> ; Laboratory lecture & instruction	3	15
S	2000/01	BMS 297A; Molecular Biology & Pathology of Neoplasia	<i>Animal Models of Cancer Laboratory</i> ; Laboratory lecture & instruction	3	15
W	2000/01	BMS 225; Tissue and Organ Biology	Lecture and laboratory instruction	3	15
S	2000/01	BMS 260; Cell Biology	Discussion group leader	1	6
F/W	2001/02	IDS 101; Prologue	Laboratory Instructor	9	30
W	2001/02	BMS 225; Tissue and Organ Biology	Lecture and laboratory instruction	3	15
W	2001/02	IDS 103; Cancer Block	<i>Invasion & Metastasis</i> ; Lecturer	7	150
S	2001/02	BMS 260; Cell Biology	Discussion group leader	1	7
F	2002/03	BMS 260; Cell Biology	Discussion group leader	1	6

W	2002/03	IDS 103; Cancer Block	<i>Invasion & Metastasis</i> ; Lecturer	7	150
F/W	2002/03	IDS 101; Prologue	Laboratory Instructor	9	30
F	2003/04	BMS 260; Cell Biology	Discussion group leader	1	6
S	2003/04	BMS 225B, Tissue and Organ Biology	Lecturer and Laboratory Instructor	1.5 - 5	tbd
W	2003/04	Biochem 297; Molecular Biology & Pathology of Neoplasia	<i>Angiogenesis</i> : Lecturer	3	30
W	2003/04	BMS 297A Molecular Biology & Pathology of Neoplasia Laboratory	Lecturer and Laboratory Instructor, <i>Animal Models of Neoplasia</i>	1	10
S	2003/04	BMS 225B; Tissue & Organ Biology	Lecturer: Cancer I & Cancer II	1.5 - 5	16
F	2004/05	BMS 260; Cell Biology	Discussion group leader	1	6
F	2005/06	BMS 260; Cell Biology	Discussion group leader	1	7
W	2006/07	Biochem 297; Molecular Biology & Pathology of Neoplasia	<i>Inflammation and Cancer</i> : Lecturer	3	30
W	2008/09	BMS230; Cellular & Molecular Biology of Cancer	Course Co-Director	3.5	22
W	2008/09	BMS230; Cellular & Molecular Biology of Cancer	Lecturer: <i>Cancer Microenvironments; Inflammation and Cancer</i>	3.5	22
W	2010/11	BMS230; Cellular & Molecular Biology of Cancer	Course Co-Director	3.5	22
W	2010/11	BMS230; Cellular & Molecular Biology of Cancer	Lecturer: <i>Tumor cell heterogeneity; Cancer Microenvironments; Inflammation and Cancer</i>	3.5	22

Postgraduate and Other Courses:

1989	M204, <i>Biochemistry Lab</i> Univ. of Calif., Los Angeles	Student Teaching Assistant for quarter long course (100 medical students)
1989	Biology 250, <i>Human Heredity</i> ; Dept. of Biology Whittier College, Whittier CA	Organized and taught entire lecture-based course (30 undergraduate students)
1990	Biology 350 & 350L, <i>Molecular Genetics</i> ; Dept. of Biology, Whittier College, Whittier CA	Organized and taught entire lecture and laboratory course (16 undergraduate students)
1990	M204, <i>Biochemistry Lab</i> Univ. of Calif., Los Angeles	Student Teaching Assistant for quarter long course (100 medical students)
1990	Biology 250, <i>Human Heredity</i> ; Dept. of Biology Whittier College, Whittier CA	Organized and taught entire lecture-based course (30 undergraduate students)
1992	Biology 350 & 350L, <i>Molecular Genetics</i> ; Dept. of Biology, Whittier College, Whittier CA	Organized and taught entire lecture and laboratory course (16 undergraduate students)
2003	Graduate <i>Oncology</i> , University of Missouri, Columbia, MS, USA	Invited Guest Lecturer: Lecture syllabus & delivered 2-hr lecture for course (15 students, graduate, medical & postgraduate fellows)
2003	Graduate Program in Cancer Biology, Stanford Univ., Stanford, CA USA	Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Cancer Biology Graduate program

2004	Graduate Program in Immunology, Stanford Univ., Stanford, CA USA	Invited Guest Lecturer: Delivered 1-hr lecture to graduate students in Immunology Graduate program
2005	UCSF Dermatology residents' Basic Science Seminar Series	Invited Guest Lecturer: Delivered 1-hr lecture to UCSF Dermatology Residents (11 M.D. and M.D., Ph.D. Residents)
2008	ISREC, Lausanne University's Biochemistry and Biology Dept, and Lausanne Branch of the Ludwig Institute	Guest Instructor: <i>Exploring the Tumor microenvironment</i> , postgraduate course. (20 PhD students, 3 hours of instruction)
2009	OOA Course: Tumor Microenvironment; The Netherlands Cancer Institute	Guest Faculty: (4.5 hours of instruction, 25 PhD students)
2010	25 th Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis: <i>From Bench to Bedside & Back</i>	Faculty member: (2 hours of instruction. 100 students)
2010	Eppley Institute for Research in Cancer, Univ. of Nebraska Medical Center. Short Course in Cancer Biology: Metastasis and the Tumor Microenvironment	Faculty member: (3 hours of instruction, 166 students)
2010	San Francisco State University, Dept of Biology Seminar Series	Guest Faculty: (1 1/2 hour of instruction, 75 students)
2011	26 th Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis:	Faculty member: (2 hours of instruction. 100 students)
2012	27 th Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis:	Faculty member: (2 hours of instruction. 100 students)
2013	28 th Annual Harvard Tumor Course: Critical Issues In Tumor Microenvironment, Angiogenesis & Metastasis:	Faculty member: (2 hours of instruction. 50 students)

High School and Undergraduate Students Supervised or Mentored:

Dates	Name	Program or School	Faculty Role	Current position
1998	Christopher Tinkle	Undergraduate, Univ. of Texas, Austin, TX, USA	Summer Research Training Program Supervisor	Ph.D. awarded 2008; M.D. awarded 2010; Resident, Rad/Onc, UCSF
2000	Adam Zucker	Undergraduate, Oberlin College, Ohio USA	Supervised Summer work	unknown
2000	Ashkan Hirari	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA, USA	Supervised Summer work	unknown
2001	Jason Reuter	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Supervised Summer work	unknown
2002	Destinee Cooper	Undergraduate, Univ. of Calif., Davis USA	Summer Research Training Supervisor	unknown

2006	Sunum Mobin	UCSF Science & Health Education Partnership: High School Intern Program	Summer Research Training Supervisor	unknown
2008-2009	Julia Lam	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Independent study (199), Mentor	B.S. awarded 2009
2010	Scott Keil	Undergraduate, The University of Glasgow, Scotland	Summer Research Training Supervisor	B.S. awarded 2012
2010-2011	Heather Chen	Undergraduate, Univ. of Calif., Berkeley, Berkeley CA USA	Summer Research Training Supervisor	unknown
2010	Amy Desalazar	Cupertino High School Cupertino, CA USA	Summer Research Training Supervisor	unknown
2010-2011	Nikhil Wadhvani	Undergraduate, Sarah Lawrence College, Bronxville, NY USA	Summer Research Training Supervisor	B.S. awarded 2012
2010	Sharfa Junaid	Undergraduate, Univ. of Calif., San Diego, San Diego CA USA	Summer Research Training Supervisor	unknown
2010-2011	Jon Lau	University of Nevada, Reno, Reno, Nevada USA	Summer Research Training Supervisor	unknown
2011	Kara Wang	Undergraduate, Pomona College, Claremont, CA USA	Summer Research Training Supervisor	unknown
2011	Graham Litchman	Undergraduate, San Francisco State Univ, San Francisco CA USA	Summer Research Training Supervisor	unknown
2011	Jessica Wignall	Smith College, Northampton, MA USA	Summer Research Training Supervisor	unknown
2013	Alexander Rosenbusch	University of Erlangen-Nuremberg, Germany	Mentor	Master's Student, University of Erlangen-Nuremberg, Germany
2013	Alexandra Forsythe	Scripps College, Claremont CA USA	Summer internship Training Supervisor	Undergraduate, Scripps College

Predocctoral Students Supervised or Mentored:

Dates	Name	Program or School	Faculty Role	Current position
2000	Jin-Sae Rhee	UCSF MSTP/BMS, graduate student	Rotation Supervisor	PhD awarded 2003, M.D. awarded 2005
2000 - 2003	Jin-Sae Rhee	UCSF M.D., Ph.D.,	Ph.D. supervisor	Pediatrician, Private Sector
2000	Maria Christophorou	UCSF BMS, graduate student	Faculty coach, BMS 297	Ph.D. awarded 2006
2001	Leslie Chu	UCSF BMS, graduate student	Rotation Supervisor	Ph.D. awarded 2005
2001	Rayna Takaki	UCSF BMS, graduate	Rotation	Ph.D. awarded 2006

		student	Supervisor	
2001 – 2002	Sophia Bruggerman	University of Nijmegen, The Netherlands	Masters Thesis Supervisor	Ph.D. awarded 2007
2002	Lucy Lebedeva	UCSF PIBS, graduate student	Faculty coach, BMS 297	Ph.D. awarded 2005
2002	Leslie Chu	UCSF BMS, graduate student	Ph.D. Orals committee	Ph.D. awarded 2005
2002	Andre Whitkin	MSTP student, Cornell University USA	Supervised Summer work	unknown
2002	Karin de Visser	The Netherlands Cancer Institute, The Netherlands	Ph.D. Thesis Reading Committee	Ph.D. awarded 2002
2003	Cathy Collins	UCSF MSTP student	MSTP Advisor	PhD awarded 2009 M.D. awarded 2011
2004	Eric Tamm	University of British Columbia, Canada	Doctoral Dissertation External Examiner	Ph.D. awarded 2004
2004	Annie Hsieh	University of Södertörn, Sweden	Masters Thesis Supervisor	unknown
2005	Geoff Benton	UCSF TETRAD/PIBS, graduate student	Ph.D. Orals committee	Ph.D. awarded 2011
2006	Morgan Truitt	UCSF BMS, graduate student	Rotation Supervisor	UCSF BMS PhD graduate student
2006	Danielle Shin	UCSF MSTP student	Rotation Supervisor	Ph.D. awarded 2011
2006-2008	Celeste Rivera	SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student	M.S. research advisor	M.S. awarded 2010; Research Technician, EPFL Lausanne Switzerland
2007-2009	Leslie Vasquez	SFSU/UCSF NIH Post-baccalaureate Research Experience Program (PREP) student	M.S. research advisor	M.S. awarded 2009; PharmD student, UCSF
2008	Ashley Martin	UCSF BMS, graduate student	Rotation Supervisor	PhD awarded 2012
2009	Kay Wiebrands	Master's Student Utrecht University, the Netherlands	Masters Thesis Internship Supervisor	M.S. awarded 2009
2009-2010	David Tawfik	Medical Student III, UCSF	MSIII break year. Dean's Quarterly Research Fellowship; PACCTR Fall Quarter Fellowship;	M.D., awarded 2011; Resident in Internal Medicine, UCLA Harbor Hospital
2009-2012	Renee Vanderlaan	UCSF BMS, graduate student	Chair: Thesis Committee	PhD awarded 2012
2009-2011	A. Preethi Ganessan, M.D., PhD.	Ph.D. Graduate Student (Cancer Research UK, Univ of	Ph.D. supervisor	Pediatric Hematology Resident, Univ of Southampton, UK

		Southampton)		
2010 - 2011	Lucia Cottone	Ph.D. graduate student (San Raffaele Institute, Milan Italy)	Ph.D. supervisor and 2 nd supervisor del candidato	PhD awarded 2012
2011	Conny Hainer	Master's student, Technical University of Berlin, Berlin, Germany	MS supervisor	Master's student, Technical University of Berlin, Berlin, Germany
2011-2012	Melissa Wheeler	PharmD student, UCSF	PharmD research mentor	PharmD awarded 2013
2011-2012	Paul Huynh	PharmD student, UCSF	PharmD research mentor	PharmD awarded 2013
2012	Derek Zachman	OHSU, MD/PhD and PMCB student	Qualifying exam committee	OHSU PMCB student
2012-present	Tim Butler	OHSU, Cancer Biology graduate student, Spellman lab	Thesis committee	OHSU Cancer Biology graduate student
2012	Katelyn Atkins	OHSU, CDB graduate student	Thesis Examiner	Ph.D. awarded Sept. 2012
2013, 2014	Xiaoming Ouyang	OHSU PMCB/CanBio graduate student. Kulesz-Martin lab	Rotation supervisor; Qualifying Exam Committee	OHSU Cancer Biology student
2013-present	Shannon Liudahl	OHSU PMCB/Can Bio graduate student Coussens lab	Rotation and Thesis supervisor	OHSU Cancer Biology student
2013	Tyler Risom	OHSU Can BioGraduate Program	Qualifying Exam committee	OHSU Cancer Biology student
2014-present	Spencer Watson	OHSU Can BioGraduate Program; Gray lab	Thesis committee	OHSU Cancer Biology student

Postdoctoral Fellows and Residents Directly Supervised or Mentored

Dates	Name	Position & Funding	Faculty Role	Current Position
2000 - 2001	Ernst Lengyel, M.D., Ph.D.	Post-Doc Researcher, Senior Clinical Fellow	Research Supervisor	Professor, Dept. Gyn. & Oncology, UCSF
2000 -2002	Leon Van Kempen, Ph.D.	Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship	Research Supervisor	Assoc. Prof., Univ. of Nijmegen, Dept. of Pathology, The Netherlands
2002 – 2005	Robert Diaz, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Scientist, Roche Pharmaceuticals
2002 – 2005	Karin de Visser, Ph.D.	Post-Doc Researcher, Dutch Cancer Society Postdoctoral Fellowship	Research Supervisor	Group Leader, The Netherlands Cancer Inst, Amsterdam, The Netherlands
2003 – 2007	Alexandra Eichten, Ph.D.	Post-Doc Researcher, Serono Fndt for the Advancement of Medical Science (2003-2005);	Research Supervisor	Scientist, Regeneron Corp., New York USA
2003 - 2005	Stephen Robinson, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Private sector, United Kingdom

2003 - 2004	H. Jennifer Shen, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	unknown
2005 -2010	David DeNardo, Ph.D.	Post-Doc Researcher; 1) NGA: 5T32CA09043 PI: BISHOP; <i>Molec. Analysis of Tumor Viruses</i> ; 2) Am Cancer Society Fellowship 2007-2010	Research Supervisor	Assistant Professor, Molecular Oncology and Immunology, Washington University, St Louis, St Louis MS USA
2005 – 2007	Nor Eddine Sounni, Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Research Scientist, Univ. of Liege, Belgium
2006 – 2007	Tingting Tan, M.D., Ph.D.	Post-Doc Researcher; Coussens R01	Research Supervisor	Hem/Onc Fellow, Fox Chase Cancer Center, Phil., PA
2006 -2010	Magnus Johansson, Ph.D.	Post-Doc Researcher; Swedish Cancer Society Fellowship 2006-08	Research Supervisor	MBA candidate, Stanford Univ., Palo Alto CA
2006- 2012	Nesrine Affara, Ph.D.	Post-Doc Researcher; AACR-Astellas USA Fndt in Basic Cancer Research 2009-2010: T32 Cancer Biology 2010-2011	Research Supervisor	Maternity
2007 -2010	Pauline Andreu, Ph.D.	Post-Doc Researcher; Cancer Research Institute Postdoctoral Fellowship 2008-2011	Research Supervisor	Research Funding Agency in Private Sector, France
2008- present	Brian Ruffell, Ph.D.	Post-Doc Researcher; Dept of Defense Postdoctoral fellowship 2009-2012	Research Supervisor	Post-Doctoral fellow, Coussens Lab, UCSF, OHSU
2009-2011	Stephen Shiao, M.D., Ph.D.	UCSF Radiation Oncology Resident	Research Supervisor	Cedars Sinai Med. Ctr, Los Angeles CA
2010-2012	Collin Blakeley, M.D., Ph.D.	UCSF Hematology-Oncology Fellow; T32 Hem/Onc Training Grant 2011-2013	Research Supervisor	UCSF Hematology-Oncology Fellowship
2010-2013	Anna Wasiuk, Ph.D	Post-Doc Researcher; Coussens grant	Research Supervisor	Post-Doctoral fellow, Coussens Lab, UCSF, OHSU
2012 - present	Andrew Gunderson, Ph.D.	Post-Doc Researcher; T32, Immunology Training grant 2012-2014	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2012 - present	Tina Bose, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2012 - present	Terry Meddler, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2012 - 2013	Aubie Shaw, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Lab manager, University of Wisconsin
2012 - present	Sushil Kumar, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU
2013 – present	Christopher Chan, Ph.D.	Post-Doc Researcher; Coussens grant	Research Supervisor	Post-Doctoral fellow, Coussens Lab, OHSU

FOMRAL FACULTY MENTORING

Dates	Name	Position while Mentored	Mentoring Role	Current Position
2001 – 2004	Ernst Lengyel, M.D., Ph.D.	Asst. Adjunct Professor	Research Mentor	Prof., Dept. Gyn. & Oncology, Univ. of Chicago, Chicago, IL
2002 – 2007	Darya Soto, M.D.	Asst. Adjunct Professor,	K08 Research Mentor	Private Practice, Burlingame, CA
2005 – 2007	Runi Chattopadhyay, M.D.	Clinical Instructor and Clinical Fellow	Basic Science Mentor, K12	Private Practice, San Francisco, CA
2006 – 2011	Limin Liu, Ph.D.	Assistant Professor	Member, Mentoring Committee	Dept. of Microbiology & Immunology, Sandler Center for Basic Research in Asthma, UCSF
2010 - 2011	Jaynata Debnath, M.D., Ph.D.,	Assistant Professor	Faculty Mentor	Associate Professor, Dept. of Pathology, UCSF

Sabbatical Visitors:

1999 - 2000 Yves DeClerck, M.D. Professor, Univ. of Southern Calif. & Children's Hospital Loss Angeles

SUMMARY OF TEACHING HOURS

Academic Year	Teaching/Mentoring Summary	Hours
1997/98	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>27</u> 2 1 24
1998/99	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>71</u> 2 1 68
1999/00	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>108</u> 4 2 102
2000/01	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>130</u> 16 9 105
2001/02	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>201</u> 18 19 164
2002/03	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>314.5</u> 15.5 17 282
2003/04	Total hours of teaching /mentoring: Formal class or course teaching hours: Informal teaching hours including prep time: Mentoring hours:	<u>402</u> 20 28 354
2004/05	Total hours of teaching /mentoring:	<u>395</u>

	Formal class or course teaching hours:	17
	Informal teaching hours including prep time:	28
	Mentoring hours:	350
2005/06	<u>Total hours of teaching /mentoring:</u>	<u>395</u>
	Formal class or course teaching hours:	17
	Informal teaching hours including prep time:	28
	Mentoring hours:	350
2006/2007	<u>Total hours of teaching /mentoring:</u>	<u>473</u>
	Formal class or course teaching hours:	45
	Informal teaching hours including prep time:	28
	Mentoring hours	400
2008/2009	<u>Total hours of teaching /mentoring:</u>	<u>499</u>
	Formal class or course teaching hours:	51
	Informal teaching hours including prep time:	48
	Mentoring hours	400
2009/2010	<u>Total hours of teaching /mentoring:</u>	<u>499</u>
	Formal class or course teaching hours:	51
	Informal teaching hours including prep time:	48
	Mentoring hours	400
2010/2011	<u>Total hours of teaching /mentoring:</u>	<u>499</u>
	Formal class or course teaching hours:	51
	Informal teaching hours including prep time:	48
	Mentoring hours	400
2011/2012	<u>Total hours of teaching /mentoring:</u>	<u>460</u>
	Formal class or course teaching hours:	20
	Informal teaching hours including prep time:	40
	Mentoring hours	400
2012/2013	<u>Total hours of teaching /mentoring:</u>	<u>500</u>
	Formal class or course teaching hours:	60
	Informal teaching hours including prep time:	40
	Mentoring hours	400
2013/2014	<u>Total hours of teaching /mentoring:</u>	<u>500</u>
	Formal class or course teaching hours:	60
	Informal teaching hours including prep time:	40
	Mentoring hours	400

VI. INVITED PRESENTATIONS

Symposia and Workshops: International

- 1996 *Human Tumor Heterogeneity II: Cytometric Measurement of Growth Regulation and Genetic Alterations: International Society of Analytical Cytometry.* Kananaskas, Alberta, Canada.
- 1997 *GeneMedicine-Boehringer Mannheim Cancer Alliance: Technology Workshop.* Cancún Mexico.
- 2001 *2nd Annual International Protease Society.* Freising, Germany.
- 2002 *6th International Symposium on Predictive Oncology & Intervention Strategies,* Pasteur Institute, Paris, France
- 2002 **KEYNOTE LECTURE,** *Dutch Cancer Society Annual Symposium,* Luntern, The Netherlands
- 2002 **KEYNOTE LECTURE,** *Cancer: Genome, Signal & Environment, Takeda Genome Urology International,* Kyoto, Japan
- 2003 *2nd Annual International Symposium on Epithelial Biology,* Timberline, Oregon USA
- 2004 *10th International Congress of the Metastasis Research Society, 'Progress Against Tumor Progression',* Genoa Italy
- 2005 *2005 International Consortium Meeting of the Children's Tumor Foundation: Molecular Biology of NF1, NF2 and Schwannomatosis,* Aspen, CO, USA
- 2005 *International Symposium on Systems Genome Medicine - Bench to Bedside,* Institute of Medical Sciences University of Tokyo, Tokyo, Japan
- 2005 *Immunotherapy of Cancer, XI Annual Symposium of the Danish Cancer Society,* Copenhagen,

- Denmark
- 2005 4th General Meeting of the International Proteolysis Society, Quebec City, Canada
- 2006 Centro Nacional de Investigaciones Oncológicas (CNIO) Cancer Conference: *Inflammation and Cancer*, Madrid SPAIN
- 2006 18th Annual Pezcoller Symposium '*Tumor Microenvironment: Heterotypic Interactions*', Trento ITALY
- 2006 European Association for Cancer Research (EACR) 1st Annual Meeting, Budapest HUNGARY
- 2006 XXXIVth Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM): Tumor Biology, Detection and Therapy, Pasadena, CA, USA
- 2006 37th International Symposium of the Princess Takamatsu Cancer Research Fund '*Cancer Cells and Their Microenvironment*', Tokyo, JAPAN
- 2007 4th International Conference on Tumor Microenvironment, Florence, ITALY
- 2007 2nd International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy, San Francisco CA USA
- 2007 CNIO – Nature Symposium on "Oncogenes and Human Cancer". The Next 25 Years", Madrid SPAIN
- 2007 **KEYNOTE LECTURE**, 7th International Symposium on Hodgkin Lymphoma, Cologne, GERMANY
- 2007 **CANDLELIGHT LECTURE**, *Inflammation and Cancer: From molecular links to bed side*; Inaugural meeting for the *Istituto Clinico Humanitas*, Milan ITALY
- 2008 7th Annual International Congress on the Future of Breast Cancer, Kauai, Hawaii USA
- 2008 Cancer Research UK Cambridge Research Institute (CRI) Inaugural Annual Symposium, '*Unanswered Questions in the Tumour Microenvironment*', Homerton College, Cambridge UK
- 2008 5th International Kloster Seeon Meeting, *Angiogenesis: Molecular Mechanisms and Functional Interactions*. Kloster Seeon, GERMANY
- 2008 **CANCER RESEARCH UK LECTURE**, NCRI Cancer Conference, Birmingham UNITED KINGDOM
- 2009 21ST Lorne Cancer Conference, Lorne AUSTRALIA
- 2009 6th International Symposium on the Intraductal Approach to Breast Cancer, Santa Monica CA USA
- 2009 **STATE-OF-THE-ART LECTURE**, International Cancer Conference, *CANCER 2009*, Dublin IRELAND
- 2009 19th Annual BioCity Symposium, 'Tumor Microenvironment in Cancer Progression', Tirku FINLAND
- 2009 **KEYNOTE LECTURE**, European Association of Cancer Research, Special Conference on *Inflammation and Cancer*, Berlin GERMANY
- 2009 7th International Symposium on Minimal Residual Cancer, Athens, GREECE
- 2009 Tri-Society Annual Conference of the Society for Leukocyte Biology, International Cytokine Society, and the International Society for Interferon and Cytokine Research, Lisbon, Portugal
- 2009 5th International Conference on Tumor Microenvironment, Versailles, FRANCE
- 2009 **PRESIDENT'S PLENARY LECTURE**: Italian Cancer Society Annual Meeting, Milano ITALY
- 2010 **PLENARY LECTURE**, CHUV Research Day, University hospital (CHUV) and the Faculty of Biology and Medicine, Lausanne, SWITZERLAND.
- 2010 *NATURE - CNIO Cancer Symposium on Frontiers in Tumour Progression*, Madrid SPAIN
- 2011 Curie Institute Symposium, *Breast Cancer from Biology to Clinics*, Paris FRANCE
- 2011 EPFL Inaugural Symposium, *Hallmarks and Horizons in Cancer*, Lausanne SWITZERLAND
- 2011 Joint meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Florence, ITALY
- 2011 41st Australian Society for Immunology (ASI), Adelaide, South AUSTRALIA
- 2012 International Symposium of the Collaborative Research Center (ISRC), *Molecular Basis and Modulation of Cellular Interactions in the Tumor Microenvironment*, Cologne, Germany
- 2012 Keystone Symposium on *The Role of Inflammation During Carcinogenesis*, Dublin, IRELAND
- 2012 Federation of Clinical Immunology Societies (FOCIS) 2012, Improving Human Health Through Immunology, Vancouver, BC, CANADA
- 2012 Annual Meeting of the (French) National Institute of Cancer, Plenary session on "*Cancer Immunity and Inflammation*", Paris FRANCE
- 2012 25th International IGB Workshop, organized by the Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Capri, ITALY
- 2013 Cancer Research Center of Lyon (CRCL), First International CRCL Symposium: *A Focus on Tumor Escape*. Lyon FRANCE
- 2013 9th AACR-Japanese Cancer Association International Conference; Maui, Hawaii. USA

- 2013 3rd Meeting on Immunochemotherapy, Paris FRANCE
 2013 UK National Cancer Research Institute Annual Conference, Liverpool, UK
 2014 **ASHLEY DUNN ORATION: PLENARY LECTURE**, 26th Lorne Cancer Conference, Lorne, AUSTRALIA

UPCOMING INVITATIONS

- 2014 15th International Biennial Congress of the Metastasis research Society, Heidelberg, GERMANY
 2014 3rd International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets, Mykonos, GREECE
 2014 Cell Symposium, Hallmarks of Cancer: Asia, Beijing CHINA
 2014 Annual Frontiers in Cancer Science 2014, SINGAPORE
 2015 Annual Frontiers in Cancer Research and Therapy, Dept. of Oncology-Pathology at Karolinska Institutet, Stockholm, SWEDEN

Symposia and Workshops: National

- 1994 *Current Transgenic Technology*, B & K Universal, San Mateo, CA, USA
 1997 *Biology of Proteolysis*, Cold Spring Harbor Laboratory, NY, USA
 1997 *Molecular Biology & Pathology of Neoplasia*, AACR, Keystone, CO, USA
 1997 *Matrix Metalloproteinases*, Gordon Research Conference, Proctor Academy, New London, NH, USA
 1998 *Proteolysis*, Gordon Research Conference, Colby-Sawyer College, New London, NH, USA
 1998 *Cellular Targets of Viral Carcinogenesis*, AACR Special Conference. Dana Point, CA, USA
 1998 *Mechanisms of Tumor Growth & Invasion Mediated by Proteolysis*, UCSF-Molecular Design Institute. San Francisco, CA, USA
 1999 *Tumor Microenvironment*, Education Session, AACR Annual Meeting. Philadelphia, PA, USA
 1999 *Matrix Metalloproteinases*, Gordon Research Conference, Colby-Sawyer New London, NH, USA.
 2000 *Epithelial-Stromal Interactions & Tumor Progression Workshop*, National Cancer Inst., Bethesda, MD, USA
 2000 10th National Conference of the Inflammation Research Association, Hot Springs, VA, USA
 2001 *'Meet-the-Expert' Sunrise Session*, AACR Annual Meeting, New Orleans, LA, USA
 2002 *Chemotherapy of Experimental & Clinical Cancer*, Gordon Research Conference, Colby Sawyer College, New London, NH, USA
 2002 *Proteolytic Enzymes & their Inhibitors*, Gordon Research Conference, Colby Sawyer, New London, NH, USA
 2002 *From the Cancer Cell to a Tumor - Tumors as Outlaw Organs*, Schilling Research Conference, The American Cancer Society, Aptos CA, USA
 2002 *Cancer Intervention 2002*, Van Andel Research Institute, Grand Rapids, Michigan USA
 2002 *Pathobiochemistry B Study Section Workshop*, Natl. Cancer Institute, Hilton Head, SC, USA
 2002 *Proteases, Extracellular Matrix and Cancer*, AACR Special Conference, Hilton Head Island, SC, USA
 2002 *ECM and Cancer*, Minisymposium, ASCB Annual Meeting, San Francisco, CA, USA
 2003 *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
 2003 *Angiogenesis & Microcirculation*, Gordon Research Conference, Salve Regina, Newport R.I., USA
 2003 *Inflammatory Cells and Cancer*, Symposium, American Society of Hematology 2003 Annual Meeting, San Diego, CA, USA
 2003 *Validation of a Causal Relationship: Criteria to Establish Etiology*, National Cancer Institute, Cancer Etiology Branch, Washington, DC, USA.
 2003 *Functional Imaging of Proteolysis*, Special Session, ASCB Annual Meeting, San Francisco, CA, USA
 2004 Scleroderma Research Foundation Annual Scientific Workshop, San Francisco, CA, USA
 2004 *Systems Biology of Cancer: The Tumor as an Organ*, Symposium, 95th AACR Annual Meeting. Orlando, FL, USA
 2004 *Inflammation and Cancer*, Symposium, 95th AACR Annual Meeting. Orlando, FL, USA
 2004 *Remarkable Role of the Microenvironment in Development and Disease Pathogenesis*, Symposium; Experimental Biology 2004, Sponsored by: the Assoc. of Anatomy, Cell Biology and Neurobiology, Washington, D.C., USA.

- 2004 *Molecular and Cellular Basis of Disease: Structure and Function of the Extracellular Matrix in Disease: Novel Roles and Regulation of MMPs and TIMPs in Disease*, Symposium; Experimental Biology 2004, Sponsored by: the Am. Society of Investigative Pathology, the American Society for Matrix Biology and the North American Vascular Biology organization. Washington, D.C., USA.
- 2004 Pacific Coast Protease Workshop, Half Moon Bay, CA, USA.
- 2004 19th Aspen Cancer Conference: *Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy*. Aspen, CO, USA.
- 2005 Keystone Symposia, *The Role of Microenvironment in Tumor Induction and Progression (J5)*, Banff, Alberta CANADA
- 2005 Keystone Symposia, *Inflammation and Cancer (B8)*, Breckenridge, CO, USA
- 2005 *Symposium on Inflammation, Repair and Carcinogenesis in Liver, Pancreas and Colon*. UCSF Liver Center and the Program in Gastrointestinal Cancer of the UCSF Cancer Center, Rohnert Park, CA, USA
- 2005 *In the Forefront of Advances in Cancer Research*, Symposium, 96th AACR Annual Meeting. Anaheim, CA, USA
- 2005 *Macrophage Symposium*, AMGEN, Seattle, WA, USA
- 2005 *Immune Response to Cancer Symposium*, 41st Annual Meeting, American Society Clinical Oncology (ASCO), Orlando. FL. USA
- 2005 *Phagocyte*, Gordon Research Conference, New London, CT, USA
- 2005 *Mouse Models of Human Cancer Consortium*, Annual Steering Committee Meeting, New Brunswick, NJ USA
- 2005 *Matrix Metalloproteinases*, Gordon Research Conference, Big Sky, Montana, USA
- 2005 *Annual Buffalo Regional Conference on Immunology*, Buffalo, NY, USA
- 2005 2005 Montagna Symposium on 'Tissue repair - molecular mechanisms and clinical challenges', Salishan Lodge, OR, USA
- 2005 4th Annual AACR Conference on *Frontiers in Cancer Prevention Research*, Baltimore MD, USA
- 2005 AACR Special Conference, *Cancer, Proteases and the Microenvironment*, Bonita Springs, Florida. USA
- 2006 Timberline Annual Symposium on Epithelial Biology, *Intrinsic and Microenvironmental Regulation of Epithelial Cancer*, Timberline Lodge, Oregon, USA
- 2006 Keystone Symposium, *Molecular Targets for Cancer Prevention*, Granlibakken Resort, Tahoe City, CA, USA
- 2006 *Inflammation and Cancer*, Symposium, 97th AACR Annual Meeting. Washington, D.C., USA
- 2006 Lineberger Cancer Center's 30th Annual Scientific Symposium, University of North Carolina, Chapel Hill, North Carolina, USA
- 2006 **KEYNOTE LECTURE**, *Vanderbilt-Ingram Cancer Center Retreat 2006*, Vanderbilt University, Nashville TN, USA
- 2006 **TUMOR BIOLOGY PLENARY LECTURE**, *Advances in Neuroblastoma Research 2006*, Los Angeles, CA, USA
- 2006 *Genetic, Cellular and Microenvironmental Determinants of Tumor Progression and Metastasis: A 'TPM' Workshop Honoring Martin L Padarathsingh, Ph.D.* TPM Study Section Workshop, Natl. Cancer Institute, Georgetown, VA, USA
- 2006 ASCO/Federation of European Societies Symposium: *Inflammation in Cancer Progression*, 2006 ASCO Annual Meeting, Atlanta, GA, USA
- 2006 AACR Special Conference, *Mouse Models of Cancer*, Cambridge, MA, USA
- 2006 AACR Special Conference, *Tumor Immunology: An Integrated Perspective*. Miami, FL, USA
- 2007 7th AACR-Japanese Cancer Association Joint Conference: *In the Forefront of Basic and Translational Cancer Research*, Waikoloa, Hawaii, USA
- 2007 Keystone Symposium, *'Mouse Models at the Frontiers of Cancer Discovery'*, Whistler, British Columbia, CANADA
- 2007 Keystone Symposium *'Inflammation and Cancer'*, Santa Fe, NM, USA
- 2007 AAAS Annual Meeting, *Healthy Aging: Inflammation and Chronic Diseases'* Symposium, San Francisco, CA USA
- 2007 Tumor Microenvironment and Tumor-Stromal Interactions Workshop: Sponsored by Biogen Idec Inc., Oncology Discovery Research, San Diego CA USA

- 2007 American Thoracic Society 2007 International Conference, *San Francisco Science: Inflammation, Immunity and Signaling*. San Francisco, CA USA
- 2007 22nd Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy, Aspen CO, USA
- 2007 Gordon Research Conference, *Epithelial Differentiation & Keratinization*, Bryant University, Smithfield, RI, USA
- 2007 AACR, *Frontiers in Cancer Prevention Research Conference*, Philadelphia, PA, USA
- 2007 National Cancer Institute Workshop, '*Profiling of Immune Response to Guide Cancer Diagnosis, Prognosis and Prediction of Therapy*', Bethesda, MD, USA
- 2008 47th Midwinter Conference of Immunologists, '*Meeting the challenge: Immunobiology in health and disease*', Asilomar, CA USA
- 2008 AACR-TREC-NCI Conference on *Energy Balance and Cancer: Mediators and Mechanisms*, Lansdowne, VA USA
- 2008 Keystone Joint Symposium, '*Cell Death in the Immune System / Cell Death and Cellular Senescence*', Beaver Run Resort in Breckenridge, CO, USA
- 2008 Keystone Symposium, '*Inflammation, Microenvironment and Cancer*', Snowbird Resort in Snowbird, Utah, USA
- 2008 **THE JOHN F. ANDERSON MEMORIAL LECTURE IN MEDICINE**, '*The Linkage between Inflammation and Cancer*', University of Virginia, Charlottesville VA, USA
- 2008 *Tumor Microenvironment Symposium*, Stony Brook University, Stony Brook. NY. USA
- 2008 **KEYNOTE LECTURE**, Fox Chase Cancer Center 13th Annual Postdoctoral Fellow and Graduate Student Symposium, Philadelphia, PA USA
- 2008 DOD BCRP Era of Hope Meeting 2008, Symposium Session: *Immune and Inflammatory Contributions to Breast Cancer*, AND Era of Hope Spotlight Session, Baltimore MD, USA
- 2008 AACR Centennial Conference: *Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine*; Hyatt Regency Monterey in Monterey, CA USA
- 2008 University of Michigan Comprehensive Cancer Center 2008 Fall Symposium, Ann Arbor MI, USA
- 2008 AACR Special Conference, *Chemical and Biological Aspects of Inflammation and Cancer*, Ko Olina Hawaii, USA
- 2008 International Society for Biological Therapy of Cancer (iSBTc), Workshop on Inflammation in Cancer Development, Westin Horton Plaza San Diego, CA USA
- 2008 Skirball Symposium, New York University School of Medicine, New York, NY USA
- 2008 AACR Special Conference in Cancer Research, *Tumor Immunology: New Perspectives*; Miami FL, USA
- 2009 1st Conference on Regulatory Myeloid Suppressor Cells, Clearwater, FL USA
- 2009 Keystone Symposium, '*Extrinsic Control of Tumor Genesis*', Vancouver, British Columbia CANADA
- 2009 *Inflammation and Cancer: Novel Aspects of Protumor Immunity*, Major Symposium, 100th Annual Meeting AACR, Denver CO USA
- 2009 2nd Annual Retreat of the CCR-NCI Cancer and Inflammation Program, Gettysburg, PA USA
- 2009 24th Annual Aspen Cancer Conference, Aspen, CO, USA
- 2009 2009 Geoffrey Beane Cancer Research Symposium: *Inflammation and Cancer*, Memorial-Sloane Kettering Cancer Center, New York NY USA
- 2009 AACR Special Conference, *Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications*, San Diego CA USA
- 2009 NCI's National Tumor Microenvironment Network, Nashville TN USA
- 2010 Joint Keystone Symposia, *Role of Inflammation in Oncogenesis/Molecular and Cellular Biology of Immune Escape in Cancer*, Keystone CO USA
- 2010 3rd Annual Wyeth Discovery Frontiers in Human Disease Symposium, New York, NY USA
- 2010 **PLENARY LECTURE**, 2010 Annual Meeting of the American Association for Cancer Research, Washington DC USA
- 2010 10th Annual Oncology Research Symposium at MIT's Koch Institute for Integrative Cancer Research. Boston MA USA
- 2010 *Metastasis and the Tumor Microenvironment*, Short Course, Eppley Institute for Cancer Research, Univ of Nebraska, Omaha, NB USA
- 2010 *Cancer Cell Biology and Signaling Workshop*, ImClone Systems/Eli Lilly, New York NY, USA

- 2010 Center for Excellence in Immunology of the National Cancer Institute Symposium, Bethesda MD, USA
- 2010 *25th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis*, Boston MA, USA
- 2010 Metastasis Research Society-AACR Joint Conference on *Metastasis and the Tumor Microenvironment*, Philadelphia, PA USA
- 2010 **J. WALTER JUCKETT DISTINGUISHED LECTURE**, University of Vermont Cancer Center Clinical and Translational Research Symposium, *Inflammation & Cancer*, Burlington VT, USA
- 2010 **KEYNOTE LECTURE**, 2010 Saban Research Institute *Annual Symposium, Honoring Yves DeClerck*, University of Southern California and Children's Hospital Los Angeles, Los Angeles CA, USA
- 2010 **PLENARY LECTURE**, 2010 American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology, Concurrent Annual Meetings, Baltimore MD, USA
- 2011 **KEYNOTE LECTURE**, 11th Annual Meeting of NANT Consortium Investigators. Biology and Therapy of High Risk Neuroblastoma, Redondo Beach CA, USA
- 2011 2nd International Conference on Immunotherapy, entitled "*Immunochemotherapy: Correcting Immune Escape in Cancer*", Philadelphia PA USA
- 2011 *The Biology of Cancer: Microenvironment, Metastasis & Therapeutics*, Cold Spring Harbor Laboratory Meeting Series. Cold Spring Harbor, NY USA
- 2011 2nd NCI Tumor Microenvironment Network Junior Investigator Meeting, Cambridge, MA USA
- 2011 AACR Special Conference: *Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy*, Orlando Florida USA
- 2011 **PLENARY LECTURE**, San Antonio Breast Cancer Conference, San Antonio, Texas USA
- 2012 51st Midwinter Conference of Immunologists, Asilomar, CA USA
- 2012 **PLENARY SESSION** "Tumor Heterogeneity: Challenges and Therapeutic Opportunities" *2012 103rd Annual Meeting of the AACR*, April 3-6, 2010, Chicago, IL USA
- 2012 2012 Scientific Colloquium of the Cancer Immunotherapy Consortium. *Immune Signatures in the Tumor and Beyond: Toward Predictive and Prognostic Markers*. Baltimore Maryland, USA
- 2012 AACR Special Conference on Pancreatic Cancer, Lake Tahoe NV, USA
- 2012 CELL Symposium, *Hallmarks of Cancer*, San Francisco CA USA
- 2012 AACR Special Conference, *Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances*, Miami FL, USA
- 2012 Karmonas Cancer Institute, Wayne State University School of Medicine, Annual Symposium: Tumor & Microenvironment. Detroit, MI USA.
- 2013 **AMERICAN CANCER SOCIETY BASIC SCIENCE LECTURE**, Society of Surgical Oncology Annual Meeting, Washington D.C., USA
- 2013 Phagocytes Gordon Research Conference, Waterville Valley, NH, USA
- 2013 Salk Institute, Mechanisms and Models of Cancer Annual Symposium, La Jolla CA USA
- 2013 Society of Leukocyte Biology, *Regulators of Innate Cell Plasticity Effects in Host Defense* Newport RI, USA
- 2013 **KEYNOTE LECTURE**, 3rd Annual Women's Cancer Research Center Retreat, University of Pittsburgh Cancer Institute, Pittsburgh PA USA
- 2013 Society for Immunotherapy of Cancer, 28th Annual Meeting, National Harbor, MD, USA
- 2013 San Antonio Breast Cancer Symposium, Discussant, General Session 1. San Antonio, TX USA
- 2014 Keystone Symposium, *Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments*, Vancouver BC CANADA
- 2014 Breast Cancer Issues Conference, Portland, OR USA
- 2014 AACR Special Conference, *Cellular Heterogeneity in the Tumor Microenvironment*, San Diego, CA USA
- 2014 Keystone Symposium, *Immune Evolution in Cancer*, Whistler BC, CANADA
- 2014 AACR Annual Meeting, Major Symposium: *Translating Preclinical Trials in Genetically Engineered Mouse Models toward Clinical Trials*, San Diego, CA USA
- 2014 AACR Annual Meeting, Education Symposium: *Phenotyping Solid Tumor Stroma*, San Diego, CA USA

UPCOMING INVITATIONS

- 2015 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer, San Diego, CA USA
- 2015 **KEYNOTE SPEAKER**; Predictive Preclinical Models in Oncology conference, Molecular Medicine TriConference, San Francisco, CA USA
- 2015 Keystone Symposium on *Dendritic Cells and Macrophages Reunited*, Quebec CANADA
- 2015 Cancer Immunotherapy Symposium, Ben May Department for Cancer Research and the University of Chicago Comprehensive Cancer Center, CHICAGO IL USA
- 2015 Gordon Research Conference (GRC) "Pancreatic Diseases, Mount Holyoke College, USA

Invited Lectures/Seminars: International

- 2000 Medical Genome Center, Division of Molecular Medicine, Australian National University, Canberra, A.C.T. AUSTRALIA.
- 2001 German Cancer Center, Heidelberg, GERMANY.
- 2001 MERCK Pharmaceutical, Darmstadt GERMANY.
- 2003 University of Toronto, Ontario Cancer Institute & Princess Margaret Hospital, Toronto, Ontario, CANADA
- 2004 Cancer Research UK, Barts & The London Queen Mary's School of Medicine & Dentistry, John Vane Science Center, Charterhouse Square, London, UNITED KINGDOM
- 2004 Cancer Research UK, London Research Institute, Lincoln's Inn Fields Laboratories, London, UNITED KINGDOM
- 2004 University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, British Columbia, CANADA
- 2007 Angiogenesis and Tumor Targeting Research Unit & Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, ITALY
- 2008 Institute of Cell Biology, ETH Zurich Switzerland
- 2008 Institute of Cancer and the CR-UK Clinical Centre, Barts & The London School of Medicine and Dentistry, London UNITED KINGDOM
- 2009 University of South Hampton, UNITED KINGDOM
- 2009 The Netherlands Cancer Institute, Amsterdam, THE NETHERLANDS
- 2010 **DISTINGUISHED GUEST LECTURER**, Institute of Cancer, Barts & London School of Medicine. London UNITED KINGDOM
- 2012 Excellence in Genetics and Immunology Lecture Series, Complex Traits Group at McGill University, Montreal, Qc, CANADA
- 2012 **MILDRED SCHEEL LECTURESHIP (INNAUGURAL)**, German Cancer Aid, and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, GERMANY
- 2013 Cambridge Research Institute Distinguished Lecture, Cambridge UK.
- 2014 University of Western Australia, Harry Perkins Institute for Medical Research, Seminar Series. Perth, AUSTRALIA

UPCOMING INVITATIONS

- 2014 Lola and John Grace Distinguished Lecture in Cancer Research, Institut Suisse de Recherche Experimentale sur le Cancer (ISREC), Lausanne SWITZERLAND
- 2015 Netherlands Cancer Institute, Amsterdam, The NETHERLANDS

Invited Lectures/Seminars: National

- 1997 Biologic Therapy Research Conference. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 1997 Immunology Seminar Series. Univ. of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 1999 Axys Pharmaceuticals, South San Francisco, CA, USA
- 1999 Berlex Pharmaceuticals, Emeryville, CA, USA
- 1999 Axys Pharmaceuticals, La Jolla, CA, USA
- 1999 14th Annual Excalibur Round Table, American Cancer Society, San Francisco, CA, USA
- 1999 Colloquium in Microbiology, Cell and Molecular Biology. San Francisco State Univ., San Francisco, CA, USA
- 2000 Chiron Corporation, Emeryville, CA, USA

- 2000 Oral and Pharyngeal Cancer Branch/NIDCR, National Institutes of Health, Bethesda, MD, USA
- 2000 Fibrogen, Inc., South San Francisco, CA, USA
- 2000 Scios Inc., Sunnyvale, CA, USA
- 2000 Molecular Biology Department, University of Southern California, Los Angeles, CA, USA
- 2001 Dept. of Pediatric Hematology and Oncology, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA
- 2001 Jonnson Comprehensive Cancer Center, Univ. of Calif., Los Angeles, Los Angeles, CA, USA
- 2002 Institute for Engineering and Medicine, Univ. of Pennsylvania, Philadelphia, PA, USA
- 2002 Oncology Grand Rounds, Univ. of Missouri, Columbia, MO.
- 2002 Cancer Center, Univ. of California, Davis, Davis CA, USA
- 2002 AstraZeneca, Waltham, MA USA
- 2002 Pharmacology Seminar Series, Dept. of Pharmacology, Wayne State Univ., Detroit, MI, USA
- 2003 Dept. of Biology, Univ. of Calif., San Diego, San Diego, CA USA
- 2003 Tularik, Inc., South San Francisco, CA USA
- 2003 Dept. of Cancer Biology's Cancer Metastasis Research Program Seminar Series, M.D. Anderson Cancer Center, Univ. of Texas, Houston, TX, USA
- 2003 Dept. of Cancer Biology, Stanford University, Stanford, CA, USA
- 2004 Burnham Cancer Institute, San Diego, CA, USA
- 2004 The Wistar Cancer Institute, Philadelphia, PA, USA
- 2004 Regeneron Pharmaceuticals, Inc. Tarrytown, New York, USA
- 2004 Keynote Lecture: Vanderbilt University Digestive Disease Research Center Retreat, Vanderbilt University, Nashville, TN, USA
- 2004 Dana Farber Cancer Center, Harvard Medical School, Boston MA, USA
- 2004 Indiana University, Herman B. Wells Center for Pediatric Research and Clinical Cancer Center, Indianapolis IN, USA
- 2004 Immunology Graduate Program Seminar, Stanford University, Stanford, CA, USA
- 2005 Dept. of Nutritional Sciences & Toxicology, Univ. of Calif., Berkeley, Berkeley, CA USA
- 2005 Rigel, Inc., South San Francisco, CA USA
- 2005 Dept of Pathology & Lab Medicine, Univ. of California, Los Angeles, Los Angeles, CA USA
- 2006 Division of Cancer Biology and Angiogenesis in the Department of Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA
- 2006 Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA USA
- 2007 *Lymphoma and Myeloma Conference*, M.D. Anderson Cancer Center, Houston, TX, USA
- 2007 University of Minnesota, Dept. of Lab Medicine and Pathology, Minneapolis, MN, USA
- 2007 Memorial-Sloan Kettering Cancer Center, Program in Cancer Biology and Aging, New York NY, USA
- 2007 Abramson Family Cancer Research Institute and Univ. of Pennsylvania, Division of Hematology-Oncology, Philadelphia, PA USA
- 2007 Albert Einstein College of Medicine, New York NY, USA
- 2007 Oncology Division Research, Biogen Idec Inc., San Diego, CA USA
- 2007 Genentech, Inc. Immunology Program. South San Francisco, CA USA
- 2007 University of Iowa Carver College of Medicine, Dept of Pathology, *Pathology Grand Rounds*, Iowa City, Iowa, USA
- 2007 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
- 2007 University of Michigan, Program in Immunology and Cancer Research Series, Ann Arbor, MI USA
- 2008 Department of Pathology/UCLA School of Medicine Seminar, Los Angeles CA USA
- 2008 ANNUAL KEYNOTE LECTURE, Dept of Cancer Biology, Meharry Medical College, Nashville, TN USA
- 2008 University of California, Davis Cancer Center, Sacramento, CA USA
- 2008 Department of Immunology, University of Pittsburgh School of Medicine. Pittsburgh, PA, USA
- 2008 Cancer Biology Series, Ben May Cancer Center, University of Chicago, Chicago, IL, USA
- 2008 National Cancer Institute Center for Cancer Research Grand Rounds Series in Clinical and Molecular Oncology. Bethesda MD, USA
- 2009 University of Michigan, Oral Health Sciences Program and Biomedical Engineering Seminar Series, Ann Arbor, MI USA

- 2009 Department of Pharmacology, Wayne State University, Detroit, MI USA
- 2009 Molecular Biology Seminar Series, Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Aurora, CO USA
- 2009 National Institutes of Health/National Cancer Institute, Vascular Biology Seminar Series, Bethesda MD, USA
- 2009 Genentech, Inc., Molecular Oncology Program. South San Francisco, CA USA
- 2009 Breast Cancer Network of Strength, California Breast Cancer Organizations, Northern California Affiliate, David CA USA
- 2009 Fred Hutchinson Cancer Center, Seattle WA USA
- 2010 Cold Spring Harbor Laboratory, CSH NY USA
- 2010 Albert Einstein College of Medicine, New York, NY USA
- 2010 Department of Cell Biology & Physiology Washington University, St Louis, MO USA
- 2010 Cancer Center Seminar Series at Burnham Institute for Medical Research, San Diego CA, USA
- 2010 Oncology Seminar Series, MedImmune, Gaithersburg, MD, USA
- 2010 Immunology Institute Seminar Series, Mt Sinai School of Medicine, NY, NY USA
- 2010 San Francisco State University, Fall Seminar Series, San Francisco CA USA
- 2011 McArdle Seminar in Cancer Biology series, Univ of Wisconsin-Madison, USA
- 2011 Duke University Medical Center, Durham, North Carolina USA
- 2011 **BORNTREE DISTINGUISHED LECTURE**, Immunology and Infectious Disease Program, Dept of Veterinary and Biomedical Sciences, Pennsylvania State Univ. University Park, PA USA
- 2011 **HUCK DISTINGUISHED LECTURE**, The Huck Institute, University Park, Pennsylvania State Univ. University Park, PA USA
- 2011 Weill Cornell Medical College of Cornell University, Center for Vascular Biology, NY USA
- 2011 **CHARLES I. SIEGAL MEMORIAL LECTURE**, Dana-Farber Cancer Institute and the Dana-Farber Cancer Institute, Boston MA, USA
- 2011 Tulane Cancer Center, Hematology & Medical Oncology, Tulane Univ. School of Medicine, New Orleans, LA USA
- 2011 Northwestern University Breast Cancer Research Program and Breast Cancer Research Seminar Series, Northwestern University, Chisago IL, USA
- 2011 Novartis Institutes for Biomedical Research, Emeryville CA USA
- 2011 FivePrime Therapeutics, South San Francisco, CA USA
- 2011 Abbott Biotherapeutics, Redwood City CA USA
- 2012 Brown Foundation Institute of Medicine, Univ. of Texas, Health Science Center at Houston, Houston TX USA
- 2012 Baylor College of Medicine, Houston TX USA
- 2012 Harvard Medical School's (HMS) Committee on Immunology Seminar Series
- 2012 Massachusetts General Hospital's (MGH) Seminar Series
- 2012 University of Rochester, Department of Microbiology and Immunology, Rochester, NY, USA
- 2012 Becton, Dickinson and Company, San Jose CA, USA
- 2012 Eisai, Inc. Andover MA, USA
- 2013 University of Colorado, Denver-Anschutz Medical Campus, Cancer Biology Graduate Program Seminar. Denver, CO USA
- 2013 Earle A Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland OR. USA
- 2013 **SOSNOVSKY DISTINGUISHED LECTURESHIP**, Univ. of Wisconsin, Milwaukee, WI USA
- 2013 Maine Medical Center Research Institute, Scarborough, Maine USA
- 2014 Center for Cancer Research, National Cancer Institute, Eminent Lecture Series, Bethesda MD USA
- 2014 **KATHLEEN ROBISON HUNTSMAN DISTINGUISHED LECTURE**, Huntsman Cancer Center, Salt Lake City UT, USA
- 2014 Halozyme Inc., San Diego Ca, USA
- 2014 **GRAND ROUNDS**, Moffit Cancer Center, Tampa FL, USA
- 2014 Stanford University, Departments of Cancer Biology and Immunology, Palo Alto, CA USA

UPCOMING INVITATIONS

- 2014 Infinity Pharmaceuticals, Cambridge MA, USA
 2015 University of New Mexico, Albuquerque; "Cellular and Molecular Basis of Disease" seminar series. Albuquerque, NM USA
 2015 Fox Chase Cancer Center, Philadelphia PA, USA.
 2015 **DISTINGUISHED LECTURE**, Wistar Institute, Philadelphia PA, USA.
 2015 Pathology Grand Rounds, University of Iowa, Iowa City, IA, USA
 2015 Iowa Holden Comprehensive Cancer Center and the Interdisciplinary Graduate Program in Immunology Seminar Series, University of Iowa, Iowa City, IA, USA
 2015 Frontiers in Oncology series of University of Maryland Greenebaum Cancer Center, UM School of Medicine at Baltimore, Baltimore MD, USA

Invited Lectures/Seminars: OHSU

- 2012 OHSU Knight Cancer Biology Research Group Meeting, OHSU
 2012 OHSU School of Medicine, TEDMED 2012 Live Simulcast
 2012 **KEYNOTE**: OHSU PMCB Annual Retreat
 2012 OHSU MD/PhD Annual Retreat, McMenamans Edgefield, Troutdale, OR.
 2012 OHSU, Medical & Molecular Genetics Weekly Seminar Series
 2013 OCSSB and Dept. of Biomedical Engineering Weekly Seminar Series
 2013 OHSU Knight Cancer Institute, Annual Retreat
 2014 Marquam Hill Lecture

UPCOMING INVITATIONS

- 2014 Women's Leadership Conference at OHSU

Invited Lectures/Seminars: UCSF

- 1997 Breast Cancer SPORE Seminar. UCSF
 1999 Cancer Research Institute Retreat, Tomales Bay, CA
 2000 Chemistry and Cancer: How Chemistry-Based Tools Are Helping Solve Today's Serious Health Problems, Dev. & Alumni Relations, UCSF
 2000 Oncology Grand Rounds, Department of Hematology and Oncology, UCSF
 2000 PIBS-Cell Biology Seminar Series, UCSF
 2000 Pathology and Lab Medicine Grand Rounds, UCSF
 2000 BMS Student Pizza Talk, UCSF
 2000 Cell Cycle & Dysregulation Club, Comprehensive Cancer Center, UCSF
 2000 Comprehensive Cancer Center Retreat, Granlibakken, Tahoe City, CA
 2001 BMS Student Pizza Talk, UCSF
 2001 Pathology and Lab Medicine Grand Rounds, Departments of Medicine and Pathology, UCSF
 2001 UCSF, Cell Biology Retreat, Wilbur Hot Springs, CA, USA
 2001 UCSF TETRAD Retreat, Granlibakken, Lake Tahoe, CA, USA
 2001 UCSF Cancer Research Institute/BMS Retreat, Granlibakken, Lake Tahoe, CA. USA
 2002 Current Topics in Medical Science, UCSF Medical Scientist Training Program (M170.09)
 2002 Mouse Models of Human Cancer Program, Comprehensive Cancer Center, UCSF
 2002 Cancer Research Institute Retreat, Santa Cruz, CA
 2003 PIBS Student Pizza Talk, UCSF
 2003 Breast Oncology Program, Comprehensive Cancer Center, UCSF
 2003 Comprehensive Cancer Center Faculty Retreat: *Identification and Functional Assessment of Cancer Effectors*, Golden Gate Club, San Francisco CA
 2004 BMS Graduate Program Retreat, Granlibakken Tahoe City, CA
 2005 BMS Student Pizza Talk, UCSF
 2006 *Introduction to Research*, Department of Pathology, UCSF
 2008 Division of Experimental Medicine, Divisional Seminar Series, UCSF
 2009 Immunology Program, UCSF
 2009 Helen Diller Family Comprehensive Cancer Center *Research Symposium*; UCSF
 2010 Bay Area Workshop on Lung Development, Physiology and Cancer, San Francisco CA USA
 2010 UCSF-GIVI Center for AIDS Research (CFAR) Scientific Symposium for 2010: *HIV Infection*,

Inflammation, and Premature Aging, San Francisco, CA USA

- 2010 Breast Oncology Program Seminar, Helen Diller Family Comprehensive Cancer Center, UCSF
 2011 Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF
 2012 Breast Oncology Program Annual Retreat, Helen Diller Family Comprehensive Cancer Center, UCSF

VII. RESEARCH AND CREATIVE ACTIVITIES

Research Program: The Coussens lab focuses on the role of immune cells and their mediators as critical regulators of cancer (squamous cancer of the skin, non small cell lung cancer, mesothelioma, breast and pancreas cancer) development. During the early development of cancer, many physiological processes occur in the vicinity of 'young tumor cells' that are similar to processes that occur during embryonic development and to healing of wounds in adult tissue, e.g., leukocyte recruitment and activation (inflammation), angiogenesis (development of new blood supply) and tissue remodeling. During tumor development; however, instead of initiating a 'healing' response, activated leukocytes provide growth-promoting factors that help tumors grow, in combination with factors that inhibit cytotoxic activities of CD8⁺ T cells. We are interested in understanding the molecular mechanisms that regulate leukocyte recruitment into neoplastic tissue and subsequent regulation those leukocytes exert on evolving cancer cells. To address these issues, we have taken several approaches to investigate mechanisms involved in: *i.* induction and maintenance of chronic inflammatory microenvironments in premalignant, malignant and metastatic tissues, *ii.* role of leukocyte in regulating tissue remodeling, angiogenesis, immune suppression and cancer development, and *iii.* development of novel non-invasive imaging reagents to monitor immune response in tissues/tumors. The long-term goal of this work is to translate basic observations made in the mouse, toward rational design of novel therapeutics whose aim will be to block and/or alter rate-limiting events critical for solid tumor growth, maintenance or recurrence in humans. Currently, we are actively utilizing transgenic mouse models of solid tumor development (non-small cell lung cancer, non-melanoma squamous and breast cancer, pancreatic adenocarcinoma, and mesothelioma) to reveal the functional roles of adaptive and innate leukocytes during tumor development, and to identify new targets for anti-cancer therapy. These experimental studies are conducted in parallel with evaluation of representative human cancer specimens to affirm that mechanisms revealed in the experimental setting represent fundamental parameters of multi-stage cancer development in humans.

RESEARCH AWARDS AND GRANTS:

CURRENT

SU2C-AACR-DT12-14 (PI: Jafee, E; Vonderheide R) 07/01/14-06/31/17
Source: AACR-SU2C \$457,656 directs/yr

Title: *Transforming pancreatic cancer from a death sentence into a treatable disease*

The major goals of this program are to: 1) Develop novel immune strategies that target patient-unique T cell epitopes in pancreatic ductal adenocarcinoma (PDA) identified by tumor exome sequencing; 2) Conduct a series of "shovel ready" combination clinical trials in PDA and establish biomarkers of tumor microenvironment (TME) reprogramming – each trial focusing on a novel immune suppressive pathway within the TME; and, 3) Conduct pre-clinical studies in mouse models of PDA to establish novel combinatorial approaches and develop biomarkers that will drive the next generation of PDA clinical trials

Role: Dream Team Principal

1U54CA163123-01 (multiPI: Coussens, LM; Krummel, M) 09/23/11 – 07/31/16
Source: NIH/NCI \$258,900 directs/yr

Title: *Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes*

The major goals of this study are to: identify myeloid- and lymphoid-based biomarkers representing either functional mediators of immune cell phenotype or instead reflecting leukocyte composition, and which of these in turn represent predictive variables for predicting breast cancer response to CTX +/- macrophage-depletion therapy

Role: multi P.I.

W81XWH-10-BCRP-EOHS-EXP (PI: Coussens, LM) 09/30/11 – 09/29/16
Era of Hope Scholar Expansion Award

Source: DOD/U.S. Army Medical Research & Materiel Command \$498,935 directs/yr
Title: *Modulating Immune Response to Improve Therapy for Breast Cancer*
 The major goals of this study are to: test the hypothesis that the immune microenvironment in breast cancer can be effectively manipulated therapeutically to limit breast cancer recurrence and extend overall survival
Role: P.I.

R01 CA155331 (PI: Coussens, LM) 05/01/11 – 03/31/16
Source: NIH/NCI \$207,500 directs/yr
Title: *Regulating the Immune Microenvironment in Breast Cancer*
 The major goal of this study is to evaluate the efficacy of T_H2-blockade as a therapy for reprogramming pro-tumor immune cells in mouse models of mammary carcinogenesis.
Role: P.I.

KG111084 (multiPI: Coussens, LM; Hwang S, Rugo H) 07/01/11 – 06/31/16
Source: Komen Foundation, PROMISE Grant \$1,320,969 directs/yr
Title: *Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages.*
 The major goals of this study are to: test the hypothesis that that macrophages in triple negative (TN)/basal-like breast cancer potentiate late-stage disease progression and limit long-term survival, and that by either minimizing tumor associated macrophages (TAM) recruitment or reprogramming TAM bioactivity, outcomes for patients with TN/basal-like breast cancer will significantly improve..
Role: multi P.I.

KG110560 (multiPI: Hwang S; Coussens, LM) 07/1/11 – 06/31/14
Source: Komen Foundation, IDEA Award \$200,000 directs/yr
Title: *Immune and Collagen Basis of Breast Cancer Risk*
 The major goals of this study are to: establish whether immune and collagen status is correlated with density-associated breast cancer risk.
Role: multi P.I.

BCRF (PI: Rugo) 10/01/12-09/30/14
Source The Breast Cancer Research Foundation
Title: *Cellular mechanisms of resistance to antiangiogenic and the impact of immune therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer*
 The major goals of this study are to: 1) evaluate significance of immune cells in primary mammary carcinomas and lung metastases in the context of response and relapse/resistance to anti-angiogenic and/or immune modulating therapy, 2) Investigate the impact of inhibiting immune cell infiltration alone or in combination with antiangiogenic agents or chemotherapy on the growth of primary tumors and metastases, and 3) characterize the expression of a specific set of genes and gene copy number in circulating tumor cells (CTCs) in patients with ABC, including markers of response and resistance to specific types of therapy.
Role: subcontract P.I.

PREVIOUS

USPHS 5 T32 CA09056 (PI: Fox, F, UCLA) 07/01/89 –06/30/92
Source: NIH/UCLA \$9,300 directs/yr1
Title: *Regulation of junB Gene Expression by TGF-Beta* \$25,800 directs/yr 1-3
 Competitive Pre-Doctoral award to study transcription factor *junB*.

Univ. of Calif., Dissertation Year Fellowship (PI: Coussens, LM, UCLA) 10/1/92 – 09/31/93
Source: University of California, Office of the President \$13,350 directs/yr
Title: *Effects of E1A on TGF-Beta-inducible junB Expression*
 Competitive Pre-Doctoral award to study transcription factor *junB*.

USPHS 5 T32 CA09043 (PI: Bishop, KM, UCSF) 10/01/93-06/31/96
Source: NIH/UCSF \$25,000 directs/yr
Title: *Molecular Analysis of Tumor Viruses* \$75,000 directs/yr 1-3

 Post-Doctoral fellowship to study mouse model of epithelial carcinogenesis.

American Social Health Association/Pfizer Post-Doctoral Research Fellowship in Sexually Transmitted Diseases (PI: Coussens, LM, UCSF) 10/01/96 – 9/30/98

Source: Private Foundation \$27,500 directs/ yr 1

Title: *Metalloproteinases and Malignant Progression of Squamous Epithelium in K14-HPV16 Transgenic Mice* \$56,250 directs/yr 1-2

Role: Principal Investigator

Competitive Post-Doctoral fellowship to study proteases and tumor development

P01 CA072006 (PI: Shuman M, UCSF) 06/10/97 – 06/30/03

Source: NIH/NCI \$803,021 directs/yr 1

Title: *Proteases in Cancer Biology and Drug Development* \$4,280,649 directs/yr 1-5

Project 3 – Proteases in Models of Tumor Initiation/Progression \$165,438 directs/yr 1

Role: Co-Investigator, Project 3 \$940,281 directs/yr 1-5

The major goal of this project was to study the role of proteases in cancer biology. \$72,595 directs/yr 1

Core C – Transgenic Animal Models \$470,620 directs/yr 1-5

Role: Director (year 4 and 5)

The major goal of this Core is to develop and provide protease null and transgenic mice to program projects.

UCSF IRG-97-150-01 (PI: Coussens LM, UCSF) 07/01/99-06/30/00

Source: American Cancer Society \$20,000 directs/yr

Title: *Proteases and Genomics in a Mouse Model of Epithelial Cancer* \$20,000 directs/yr 1

Role: Principal Investigator

Pilot project tested role of proteinases as effectors of genomic instability.

UCSF Cell Cycle and Dysregulation Program (PI: Coussens LM, UCSF) 02/01/00-01/31/01

Source: UCSF Comprehensive Cancer Center, Intramural \$14,000 directs/yr 1

Title: *Epithelial Neoplastic Progression and Degradation of Type I Collagen* \$14,000 directs/yr 1

Role: Principal Investigator

Pilot project assessed functional significance of type I collagen metabolism during epithelial carcinogenesis.

Research Evaluation & Allocation Committee (PI: Coussens LM, UCSF) 07/01/00-06/30/01

Source: UCSF Academic Senate \$30,000 directs/yr 1

Title: *Role of Gelatinase B in Maintenance of Genomic Instability* \$30,000 directs/yr 1

Role: Principal Investigator

Pilot project tested the role of MMP9 as an indirect regulator of genomic instability.

UCSF IRG AC-04-02 (PI: Coussens LM, UCSF) 10/01/00-09/30/01

Source: American Cancer Society \$20,000 directs/yr 1

Title: *Regulation of Intracellular Signaling Pathways by Gelatinase B/MMP-9* \$20,000 directs/yr 1

Role: Principal Investigator

Pilot project to study signal transduction pathways regulated by MMP-9.

The V Foundation for Cancer Research (PI: Coussens LM, UCSF) 06/02/00-05/31/02

Source: Private Foundation \$50,000 directs/yr 1

Title: *Gelatinase B and Epithelial Cancer Development* \$100,000 directs/yr 1-2

Role: Principal Investigator

Pilot project to study role of MMP9 during epithelial carcinogenesis.

Gertrude B. Elion Cancer Research Award (PI: Coussens LM, UCSF) 07/1/01 – 06/30/02

Source: American Association of Cancer Research \$50,000 directs/yr 1

Title: *Functional Role of MMP-2 During Epithelial Carcinogenesis* \$50,000 directs/yr 1

Role: Principal Investigator

Pilot project to study role of MMP-2 during epithelial carcinogenesis.

Univ. of Calif., Cancer Research Coordinating Committee (PI: Coussens) 07/01/01 – 06/30/02

LM, UCSF)

Source: University of California \$48,874 directs/yr 1
Title: *Gelatinase A/MMP-2 and Epithelial Cancer Development* \$48,874 directs/ yr 1
Role: Principal Investigator
Pilot project to study role of MMP-2 as a potentiator of tumor development.

Hellman Family Award For Early Career Faculty (PI: Coussens LM, UCSF) 11/01/00-09/30/02
Source: UCSF Intramural \$49,000 directs/ yr 1
Title: *Paracrine Regulation of Epithelial Carcinogenesis by MMP-9* \$89,000 directs/yr 1-2
Role: Principal Investigator
Pilot project to identify matrix molecules regulated by MMP-9.

Edward Mallinckrodt, Jr. Foundation (PI: Coussens LM, UCSF) 10/01/00-09/30/03
Source: Private Foundation \$61,000 directs/yr 1
Title: *Regulation of epithelial cancer by gelatinase B/MMP-9* \$194,000 directs/yr 1-3
Role: Principal Investigator
Pilot project to determine how MMP-9 regulates proliferation, VEGF bioavailability and angiogenesis during epithelial carcinogenesis.

P50 CA58207 (PI: Gray, J: UCSF) 03/01/03-02/28/05
Source: NIH/NCI \$50,000 directs/yr 1
Bay Area Breast Cancer Translational Research Program (SPORE) \$100,000 directs/yr 1-2
Title: *Type I Collagen Remodeling and Mammary Carcinogenesis*
Role: Principal Investigator (Developmental Project)
The overall goal of this pilot project was to explore the role of collagen metabolism during mammary carcinogenesis.

DE-FG02-05ER6401 (PI: Franc, B; UCSF) 03/01/05 – 01/16/06
Source: DOE Medical Applications Grant \$225,100 directs yr 1
Title: Therapeutic Radionuclide Tumor-targeting Strategy for Breast Cancer \$1,125,500 total directs
Role: Co-Investigator
The specific aim of this project were to develop a radionuclide delivery molecule (RDM) that specifically targets cancer cells that express matrix-metalloproteinase-14 (MMP-14) on their surface and demonstrate delivery of radiolabeled RDM to MMP-14 expressing cells *in vitro* and *in vivo*.

R01 DK067678 (PI: Cher, M: Wayne State University) 07/01/03-06/30/06
Source: NIH/NIDDK \$14,675 directs/yr 1
Title: *Proteases in Prostate Cancer Bone Metastasis* \$122,794 directs/yr 1-4
Role: Subcontract Principal Investigator
The major goal of this subcontract is to assist with the planned experiments by providing mice (protease deficient) of defined genotype for proposed studies to analyze proteases during prostate metastasis to bone *in vivo*.

Opportunity Award, Sandler Family (PI: Coussens, LM; UCSF) 02/15/05 -02/14/07
Source: UCSF Intramural \$95,000 directs yr 1
Title: *B Lymphocytes as Targets for Cancer Prevention* \$191,000 total directs
Role: Principal Investigator
The major goal of this project was to investigate the efficacy of targeting B cells for chemoprevention

DAMD17-02-1-0693 (PI: Sloane, B; Wayne State University) 08/01/02-07/31/06
Source: Department of Defense \$5,746,832 directs/yr 1-4
Breast Cancer Center of Excellence \$49,576 directs/yr 1
Title: *Validation of Proteases as Therapeutic Targets in Breast Cancer Functional Imaging of Protease Expression, Activity and Inhibition*
Role: Subcontract Principal Investigator \$198,307 directs/yr 1-4
The goal of this program was to validate proteases as therapeutic targets in breast cancer by functional imaging of protease expression, activity and inhibition.

R01 CA94168 (PI: Coussens, LM: UCSF) 04/01/02-06/31/07

Source: NIH/NCI	\$222,500 directs/yr 1
Title: <i>Regulation of Epithelial Cancer by MMP-9/gelatinase B</i>	\$1,112,500 directs/yr 1-
Role: Principal Investigator	
The goal of this project was to identify molecules that mediate proliferative and cellular pathways activated by MMP-9.	
U54 RR020843 (PI: Smith, J; Burnham Institute)	09/30/04-07/31/06
Source: NIH/National Center for Research Resources	\$1,916,878 directs/yr 1-5
Title: Center on Proteolytic Pathways	
Role: Principal Investigator (Driving Biological Problem #1)	\$67,306 directs/yr
DBP#1 <i>Proteolytic Pathways in Acute Vascular Response</i>	
P01 CA72006 (PI: Werb, Z; UCSF)	07/07/03 – 06/30/08
Source: NIH/NCI	\$1,523,691 directs/yr 6
Title: <i>Proteases in Cancer Biology and Drug Development</i>	\$6,354,685 directs/yr 6-11
Project 3 - <i>Proteases in Models of Tumor Initiation/Progression</i>	\$229,788 directs/yr 6
Role: Co-Investigator, Project 3	\$1,172,879 directs/yr 6-11
The major goal of this project was to study the role of proteases in cancer biology.	
Core C - <i>Transgenic Animal Models</i>	\$151,612 directs/yr 6
Role: Director	\$765,974 directs/yr 6-11
The major goal of this Core was to develop and provide protease null and transgenic mice to program projects.	
R01 CA98075 (PI: Coussens, LM; UCSF)	07/01/03-06/30/09
Source: NIH/NCI	\$222,500 directs/yr 1
Title: <i>Microenvironmental Regulation of Tumor Progression</i>	\$1,112,500 directs/yr 1-5
Role: Principal Investigator	
The overall goal of this grant was to determine the role of collagen metabolism on epithelial carcinogenesis.	
P50 CA58207 (van 't Veer; UCSF)	08/01/92–11/30/12
Source: NIH/NCI	
Bay Area Breast Cancer SPORE	
Career Development and Developmental Research Award Multi Project PI: Weaver, Hwang, Coussens	(5/1/10-04/30/11)
Title: Risk to Malignancy and Immune and Collagen Status	
The goals of this project were to 1) Determine whether immune infiltrate and collagen heterogeneity exist between and within multiple regions of breast tissue, 2) Evaluate whether malignant progression is associated with a distinct immune infiltrate and if that is reflected by physical state of collagen, and 3) Determine relationship between immune infiltrate, collagen, radiographic density and clinical measures of cancer risk.	
Role: Multi P.I.	
P50 CA58207 (van 't Veer; UCSF)	08/01/92–11/30/12
Source: NIH/NCI	\$40,000 (project expenses only)
Title: Bay Area Breast Cancer SPORE	
Career Development and Developmental Research Award, Multi Project PI: Boudreau N; Coussens LM	(5/1/10-04/30/11)
Title: Macrophage-Mediated Delivery of the Breast Tumor Suppressor HoxD10 via Autologous Transfer to Breast Tumors. The aims of this project were to 1) establish function and optimize introduction of the engineered HoxD10 protein into macrophages and/or monocytes; 2) visualization of modified monocyte/macrophage accumulation in mammary tumors in vivo and 3) analysis of the impact of monocyte/macrophage delivered HoxD10 on breast tumor growth, progression and metastasis in MMTV-PyMT mouse model of mammary carcinogenesis.	
Role: Multi P.I.	
BC051640 Era of Hope Scholar Award (PI: Coussens, LM; UCSF)	06/01/06 – 05/31/11
Source: DoD, U.S. Army Medical Research and Materiel Command	\$443,205 directs yr

Title: Microenvironment Regulation of Mammary Carcinogenesis

The goal of this Scholar Award was to identify leukocytes and their proteases that modify breast carcinogenesis and to develop noninvasive imaging reagents targeting leukocytes to image inflammation.

Role: P.I.

W81XWH-08-PRMRP-IIRA (multiPI: Broaddus, C; Coussens, LM) 07/01/09 –06/30/12

Source: DoD, U.S. Army Medical Research and Materiel Command \$293,637 directs/yr

Title: Role of Macrophage-induced Inflammation in Mesothelioma

The goals of this project were 1) to determine the functional significance of macrophage phenotype in mesothelioma, 2) to determine the functional significance of macrophages as regulators of mesothelioma apoptosis in vitro and 3) to define the functional significance of macrophage depletion or repolarization on mesothelioma survival in vivo.

Role: multi P.I.

1S10OD010348-01 (PI: Coussens, LM) 06/01/2012 – 05/31/2013

Source: NIH \$403,978 directs/yr

Title: Vevo 2100 Ultrasound System

The goal of this shared instrument grant was to purchase a Vevo 2100 Ultrasound System for imaging tumor development in mouse models of cancer for the Mouse Barrier Facility at UCSF.

Role: multi P.I.

RO1 CA132566 (multiPI: Coussens, LM; Jablons DM) 05/01/08-04/30/13

Source: NIH/NCI \$190,000 directs/yr

Title: Inflammation and Lung Carcinogenesis

The goal of this study was to determine how inflammation and Wnt signaling regulate stem cell niche autonomy during lung carcinogenesis

Role: multi P.I.

R01CA140943 (multiPI: Coussens, Boudreau, Daldrup-Link) 07/01/09 –05/31/14

Source: NIH/NCI \$166,000 directs/yr

Title: *Improved Imaging and Drug Delivery Using Novel Approaches to Regulate Tissue Perfusion*

The major goals of this project are to: examine how short-term inhibition of ALK5 in vivo alters hemodynamics and tissue perfusion in mouse models of cancer.

Role: multi P.I.

RO1 CA130980 (PI: Coussens, LM) 07/01/08-05/31/14

Source: NIH/NCI \$207,500 directs/yr

Title: *Regulation of Inflammation-Associated Epithelial Cancer Development*

The major goals of this project are to: determine regulatory programs activating chronic inflammation during squamous carcinogenesis

Role: P.I.

VIII. PEER-REVIEWED PUBLICATIONS

1. Francke U, de Martinville B, **Coussens L**, Ullrich A. (1983) The human gene for the Beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. *Science* 222:1248-1251. PMID: 6648531
2. Breakefield X, Castiglione C, **Coussens L**, Axelrod F, Ullrich A. (1984) Structural gene for Beta-nerve growth factor is not defective in familial dysautonomia. *Proc. Natl. Acad. Sci. USA* 81:4213-4216. PMID: 6330750
3. Ullrich A, **Coussens L**, Hayflick J, Dull T, Gray A, Tam A, Lee J, Yarden Y, Libermann T, Schlessinger J, Downward J, Bye J, Whittle N, Waterfield M, Seeburg P. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309:418-425. PMID: 6328312
4. Ullrich A, Bell J, Chen E, Herrera R, Petruzzelli L, Dull T, Gray A, **Coussens L**, Liao Y-C, Tsubokawa M, Mason A, Seeburg P, Grunfield C, Rosen O, Ramachandran J. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 313:756-761. PMID: 2983222
5. Lauffer L, Garcia P, Harkins R, **Coussens L**, Ullrich A, Walter P. (1985) Topology of the signal recognition particle receptor in the endoplasmic reticulum membrane. *Nature* 318:334-338. PMID:

2999608

6. Schechter A, Hung M-C, Vaidanathan L, Weinberg R, Yang-Feng T, Francke U, Ullrich A, **Coussens L**. (1985) The *neu* gene: An *erbB*-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science* 229:976-978. [PMID: 2992090](#)
7. **Coussens L**, Yang-Feng T, Liao T-C, Chen E, Gray A, McGrath J, Seeburg P, Libermann T, Schlessinger J, Francke U, Levinson A, Ullrich A. (1985) Tyrosine kinase receptor with extensive homology to the EGF receptor shares chromosomal location with *neu* oncogene. *Science* 230:1132-1139. [PMID: 2999974](#)
8. **Coussens L**, Van Beveren C, Smith D, Chen E, Mitchell R, Isacke C, Verma I, Ullrich A. (1986) Structural alteration of viral homologue of receptor proto-oncogene *fms* at carboxyl terminus. *Nature* 320:277-280. [PMID: 2421165](#)
9. Parker P, **Coussens L**, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield M, Ullrich A. (1986) The complete primary structure of protein kinase C—the major phorbol ester receptor. *Science* 233:853-859. [PMID: 3755547](#)
10. **Coussens L**, Parker P, Rhee L, Yang-Feng T, Chen E, Waterfield M, Francke U, Ullrich A. (1986) Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. *Science* 233:859-866. [PMID: 3755548](#)
11. **Coussens L**, Rhee L, Parker P, Ullrich A. (1987) Alternative splicing increases the diversity of the human protein kinase C family. *DNA* 6:389-394. [PMID: 3677994](#)
12. Yarden Y, Kuang W-J, Yang-Feng T, **Coussens L**, Munemitsu S, Dull T, Schlessinger J, Francke U, Ullrich A. (1987) Human proto-oncogene *c-kit*: A new cell surface receptor-tyrosine kinase for an unidentified ligand. *EMBO J.* 6:3341-3351. [PMID: 2448137](#)
13. MacDonald R, Pfeffer S, **Coussens L**, Tepper M, Brocklebank C, Mole J, Anderson J, Chen E, Czech M, Ullrich A. (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. *Science* 239:1134-1137. [PMID: 2964083](#)
14. Formby B, Ullrich A, **Coussens L**, Walker L, Peterson C. (1988) Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islets. *J. Clin. Endo. Metab.* 66:1075-1079. [PMID: 3283160](#)
15. Mosthaf L, Grako D, Dull T, **Coussens L**, Ullrich A, McClain D. (1990) Functionally distinct insulin receptors generated by tissue-specific alternative splicing. *EMBO J.* 9:2409-2413. [PMID: 2369896](#)
16. **Coussens LM**, Yokoyama K, Chiu R. (1994) Transforming Growth Factor b₁-mediated induction of *junB* is selectively inhibited by expression of Ad.12-E1A. *J. Cell. Physio.* 160:435-444. [PMID: 8077281](#)
17. **Coussens LM**, Hanahan D, Arbeit J. (1996) Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. *Am. J. Pathol.* 149:1899-1917. [PMCID: PMC1865365](#)
18. **Coussens LM**, Werb Z. (1996) Matrix metalloproteinases and the development of cancer. *Chemistry and Biology* 3:895-904. [PMCID: PMC8939708](#)
19. Bergers G, Hanahan D, **Coussens LM**. (1998) Angiogenesis and apoptosis are cellular parameters regulating neoplastic progression in transgenic mouse models of tumorigenesis. *Int. J. Dev. Biol.* 42:995-1002. [PMID: 9853830](#)
20. **Coussens LM**, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey, GH, Hanahan D. (1999) Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. *Genes & Development* 13:1382-1397. [PMCID: PMC316772](#)
 - Featured as journal cover image
21. McKerrow JM, Bhargava V, Hansell E, Kuwahara T, Matley M, **Coussens LM**, Warren R. (2000) A functional proteomics screen of proteases in colorectal carcinomas. *Molecular Medicine* 6:450-460. [PMID: 10952024](#)
22. Bergers G, **Coussens LM**. (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases. *Curr. Opin. Genetics & Development* 10:120-127. [PMID: 10679388](#)
23. **Coussens LM**, Tinkle CL, Hanahan DH, Werb Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 103:481-490. [PMCID: PMC2843102](#)
24. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, **Coussens LM**. (2002) Epithelial carcinogenesis: Dynamic interplay between neoplastic cells and their microenvironment. *Differentiation* 70: 610-623. [PMID: 12492502](#)
25. **Coussens LM**, Fingleton B, Matrisian LM. (2002) Matrix metalloproteinases and cancer: Trials and tribulations. *Science* 295:2387-2392. [PMID: 11923519](#)

26. **Coussens LM**, Werb Z. (2002) Inflammation and cancer. *Nature* 420: 860-867. [PMCID: PMC2803035](#)
27. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, **Coussens LM**, Hanahan D. (2003) Immune enhancement of skin carcinogenesis by CD4⁺ T cells. *J Exp. Med*, 197:1017-1028. [PMCID: PMC2193878](#)
28. van Kempen LCL, Ruitter DJ, van Muijen GNP, **Coussens LM**. (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. *Euro J Cell Biol*, 82:539-548. [PMID: 14703010](#)
29. Rhee JS, Diaz R, Korets L, Hogson G, **Coussens LM**. (2004) TIMP-1 alters susceptibility to carcinogenesis. *Cancer Research* 64:952-961. [PMID: 14871825](#)
30. Chantrain CF, Shimada H, Groshen S, Ye W, Shalinsky DR, Werb Z, **Coussens LM**, DeClerck YA. (2004) Stromal matrix metalloproteinase-9 (MMP-9) regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. *Cancer Research* 64:1675-1686. [PMID: 14996727](#)
31. Baluk P, Raymond WW, Ator E, **Coussens LM**, McDonald DM, Caughey GH. (2004) Matrix metalloproteinase-2 and -9 expression increases in mycoplasma-infected airways but is not required for vascular remodeling. *Am J Physiol Lung Cell Mol Physiol*, 287:307-317. [PMID: 15075248](#)
32. de Visser KE, Korets LV, **Coussens LM**. (2004) Early neoplastic progression is complement-independent. *Neoplasia* 6: 768-776. [PMCID: PMC1531681](#)
33. Jodele S, Chantrain CF, Blavier L, Crooks GM, Shimada H, **Coussens LM**, DeClerck YA. (2005) The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9-dependent. *Cancer Research*, 65: 3200-3208. [PMID: 15833851](#)
34. de Visser KE, Korets LV, **Coussens LM**. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer Cell* 7:411-423. [PMID: 15889249](#)

Featured in:

- *Faculty of 1000 – Exceptional (Factor 6.0)*. Authoritative evaluation by R. Abraham, Wyeth Research. <http://f1000biology.com/guardpages/evaluation/1015124/>
 - *Nature* (2005), 435:752-753. 'Inflammation by Remote Control'. A. Mantovani
 - *Cancer Cell* (2005), 7: 403-405. 'The role of the immune system in early carcinogenesis: B-ware the double-edged sword'. A. Houghton, H. Uchi, and J.D. Wolchok.
 - *Nature Reviews Immunology* (2005), 5:517. 'B cells lead the way in tumour progression'. K. Minton
 - *Nature Reviews Cancer* (2005), 5:501. 'B cells lead the way in tumour progression'. K. Minton
35. de Visser KE, **Coussens LM**. (2005) The interplay between innate and adaptive immunity regulates cancer development. *Cancer Immunology & Immunotherapy*, 54:1143-1152. [PMID: 15889249](#)
 36. de Visser KE, Eichten A, **Coussens LM**. (2006) Paradoxical roles of the immune system during cancer development. *Nature Reviews Cancer*, 6:24-37. [PMID: 16397525](#)
 37. Tlsty TD, **Coussens LM**. (2006) Tumor stroma and regulation of cancer development. *Ann Rev Pathol. Mech of Disease*, 1: 119-150. [PMID: 18039110](#)
 38. van Kempen LCL, de Visser KE, **Coussens LM**. (2006) Inflammation, Proteases and Cancer. *Euro J Cancer*, 42: 728-734. [PMID: 16524717](#)
 39. Yuan F, Verhelst HL, Blum G, **Coussens LM**, Bogoyo M. (2006) A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/Cathepsin C. *J Am Chem Society*, 128: 5616-5617. [PMID: 16637611](#)
 40. Junankar SR, Eichten A, Kramer A, de Visser KE **Coussens LM**. (2006) Analysis of immune cell infiltrates during squamous carcinoma development. *J Invest Dermatol*, 126:36-4. [PMID: 17069009](#)
 41. Tan TT, **Coussens LM**. Humoral immunity, inflammation and cancer. (2007) *Curr Opin Immunology* 19(2), 209-216. [PMID: 17276050](#)
 42. Johansson M, Tan T, de Visser KE, **Coussens LM**. (2007) Immune cells as anti-cancer therapeutic targets and tools. *J Cellular Biochemistry*, 101: 918-926. [PMID: 17265430](#)
 43. Schwartz DR, Moin K, Yao B, Matrisian LM, **Coussens LM**, Bugge TH, Fingleton B, Acuff KB, Sinnamon M, Nassar H, Krawetz SA, Linebaug BE, Sloane, BF. (2007) Hu/Mu ProtIn oligonucleotide microarray: dual species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. *Mol Cancer Res*, 5:443-454. [PMID: 17510311](#)
 44. Egeblad M, Shen HCJ, Behonick DJ, Wilmes L, Eichten A, Korets L, Kheradmand F, Werb Z, **Coussens LM**. (2007). Type I collagen is a modifier of matrix metalloproteinase 2 function in skeletal development. *Dev Dynamics*, 36:1683-1693. [PMCID: PMC2581616](#)
 - Featured as journal cover image
 45. Eichten AE, Hyun WC, **Coussens LM**. (2007) Distinctive features of angiogenesis and

- lymphangiogenesis determine their functionality during de novo tumor development. *Cancer Research*, 67:5211-5220. PMID: 17545601
- Featured as journal cover image
46. DeNardo D **Coussens LM**. (2007) Balancing Immune Response: Crosstalk Between Adaptive and Innate Immune Cells During Breast Cancer Progression. *Breast Cancer Res*, 9:212-222. PMID: PMC2206719
 47. Kopitz C, Gerg M, Bandapalli O, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, Hann von Weyhern CW, Brucher BLDM, Brand K, **Coussens LM**, Edwards DR, Kruger A. (2007) TIMP-1 promotes liver metastasis by induction of HGF-signaling. *Cancer Research*, 67:8615-8623. PMID: 17875701
 48. DeNardo DG, Johansson M, **Coussens LM**. (2008) Immune cells as mediators of solid tumor metastasis. *Cancer Metastasis Rev*. 27:11-18. PMID: PMC2865635
 49. Johansson M, DeNardo DG, **Coussens LM**. (2008) Polarized immune responses differentially regulate cancer development. *Immunol Rev.*, 222:145-154. PMID: PMC2494984
 50. Kenny H, Kaur S, **Coussens LM**, Lengyel E. (2008) Adhesion of OvCa cells to peritoneum is mediated by MMP-2 cleavage of fibronectin, *J Clin Invest*. 118(4)1367-1379. PMID: PMC2267016
 51. Wolf K, Alexander S, Schacht V, **Coussens LM**, vom Andrian U, van Rheen J, Deryugina E, Friedl P. (2009) Collagen-based cell migration models in vitro and in vivo. *Seminars Cell Dev Biol.*, 20(8): 931-941. PMID: PMC4021709
 52. Watkins GA, Jones EF, Shell MS, VanBrocklin HV, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, **Coussens LM**, Franc BL. (2009) Development of an optimized activatable MMP-14 targeted SPECT imaging probe. *Bioorganic & Medicinal Chemistry*, 17:653-659. PMID: PMC2639212
 53. DeNardo DG, Baretto JB, Andreu P, Vasquez L, Kolhatkar N, **Coussens LM**. (2009) CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell*, 16:91-102. PMID: PMC2778576
- Featured in:
- *Faculty of 1000 – Exceptional (Factor 9.0)*. Authoritative evaluation by A. Mantovani, Univ. of Milan. <http://f1000biology.com/guardpages/evaluation/1163484/>
 - *Cancer Cell* (2009), 16:81-82. 'Metastasis-Promoting Immunity: When T cells turn to the dark side' by D. Pardoll
 - *Nature Reviews Cancer* (2009) 9:609. 'Influencing bad behaviour' by N. McCarthy
 - *Nature Biotechnology* (2009) 27:828. 'Promoting metastasis' by L. DeFrancesco
 - *Nature Medicine* (2009) 15:1135. 'Not Immune' by C. Schubert
 - *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine*, 17:262-265; *Nature Medicine* 17: 278-279; *Nature Medicine*, 17:295
54. Sista AK, Knebel RJ, Tavri SA, Johansson M, DeNardo DG, Boddington SE, Kishore SA, Ansari C, Reinhart V, Coakley FV, **Coussens LM**, Daldrup-Link HE. (2009) Optical Imaging of the peri-tumoral inflammatory response in breast cancer. *J Transl Med*, 7(1): 94-100. PMID: 2780997
 55. Andreu P, Johansson M, Affara NI, Tan TT, Junankar S, Korets L, Lam J, Tawfik D, Pucci F, De Palma M, DeNardo D, de Visser KE, **Coussens LM**. (2010) FcR γ activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell*, 17(2):121-134. PMID: PMC3082507
- Featured in:
- *Cancer Cell* (2010), 17(2) 111-112. 'La mala educacion of tumor-associated macrophages: Diverse pathways and new players', by A. Mantovani
 - *Nature Reviews Immunology* (2010) 10:158 'Antibodies lend support to tumors', by, L. Byrd
 - *Faculty of 1000 – Exceptional (Factor 6.4)*. Authoritative evaluations by X. Ma (Weill Medical College of Cornell) and F. Kiefer (Max-Planck-Institute, Germany). <http://f1000biology.com/article/id/2467956>
 - *Ranked as a "Top Cancer Papers" between 2008-2011, Nature Medicine*, 17:262-265; *Nature Medicine* 17: 278-279;
 - *Nature Medicine* (2011), 17(3) 285-286. 'B Cells and Macrophages in Cancer: Yin and Yang', by A. Mantovani
56. Dennemarker J, Lohmuller T, Mayerie J, Tacke M, Lerch MM, **Coussens LM**, Peters C, Reinheckel. (2010) Deficiency for cysteine protease cathepsin L promotes tumor progression in mouse epidermis mice. *Oncogene*, 29(11):1611-1621. PMID: PMC3082505
 57. Sounni NE, Dehne K, vanKempen LCL, Egeblad M, Affara NI, Cuevas I, Wiesen J, Junankar S, Korets

- L, Lee J, Shen J, Morrison C, Overall CM, Krane SM, Werb Z, Boudreau N, **Coussens LM**. (2010) Stromal regulation of vessel stability by MMP14 and TGF β . *Disease Model. Mech.* 3:317-332. [PMCID: 2860851](#)
58. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Beltran A, Johansson M, **Coussens LM**, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons DM, He B. (2010) EMX2 is epigenetically silenced and suppresses growth in human lung cancer. *Oncogene*, 29(44):5969-5975. [PMCID: PMC3090446](#)
59. Doedens A, Stockman C, Rubenstein M, Liao D, DeNardo D, **Coussens LM**, Karin M, Goldrath A, Johnson R. (2010) Macrophage expression of HIF1 α suppresses T cell function and promotes tumor progression. *Cancer Res*, 70(90): 7465-7475. [PMCID: PMC2948598](#)
60. Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, DeNardo D, **Coussens LM**, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ (2010) Receptor tyrosine kinase signaling in breast cancer cells inhibits the adaptive immune response to favor a pro-tumorigenic state. *Cancer Res*, 70(20): 7776-7787. [PMCID: PMC3660232](#)
61. Ruffell B, DeNardo DG, Affara NI, **Coussens LM**. (2010) Lymphocytes in cancer development: Polarization towards pro-tumor immunity. *Cytokine Growth Factor Reviews*, 21:3-10. [PMCID: 2834837](#)
62. DeNardo DG, Andreu P, **Coussens LM**. (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Rev*, 29(2):309-316, [PMCID: 2865635](#)
63. Shiao SE, **Coussens LM**. (2010) The tumor-immune microenvironment and response to radiation therapy. *J Mammary Gland Biol Neoplasia*, 15:411-421. [PMCID: PMC3011087](#)
64. Masset A, Maillard C, Sounni NE, Jacobs N, Bruyere F, Delvenne P, Tacke M, Reinheckel T, Foidart JM, **Coussens LM**, Noel A. (2011) Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. *Int J Cancer*, 128:283-293. [PMCID: PMC3084626](#)
65. Erez N, **Coussens LM**. (2011) Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. *Int. J Cancer*. 128:2536-2544. [PMCID: PMC3084629](#)
66. **Coussens LM**, Pollard JW. (2011) Leukocytes in mammary development and cancer. *Cold Spring Harbor Perspectives in Biology*, 3(3) [PMCID: PMC3039933](#)
67. DeNardo DG, Brennan DJ, Rexhapaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhvani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, **Coussens LM**. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discovery*, 1(1): 54-67. [PMCID: PMC3203524](#)
- Featured in:
- *Nature* (2011), 472 303-304. 'Macrophages Limit Chemotherapy' by, M. De Palma and C.E. Lewis
 - *Nature Reviews Cancer* (2011) 11:3056. 'Bad company', by N. McCarthy
 - *2011 Most-Cited Article in CANCER DISCOVERY*, http://www.aacrjournals.org/site/SpecialPages/most_cited.xhtml
68. Benavides F, Perez C, Blando J, Contreras O, Shen J, **Coussens LM**, Fischer SM, Kusewitt DF, Digiovanni J, Conti CJ (2011) Protective role of cathepsin L in mouse skin carcinogenesis. *Mol Carcinog.* 52: 352-361 [PMCID: PMC3155742](#)
69. Barbone D, Ryan J, Kolhatkar N, Chacko A, Jablons DM, Sugarbaker DJ, Bueno R, Latei AG, **Coussens LM**, Fennel DA, Broaddus VC. (2011) The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. *Cell Death & Disease.*; 2:e174. doi: 10.1038/cddis.2011.58. [PMCID: PMC3169000](#)
70. Schioppa T, Moore R, Thompson R, Rosser E, Kulbe H, Nedospasov S, Mauri C, **Coussens LM**, Balkwill F. (2011) B regulatory cells and the tumor-promoting actions of TNF-(alpha) during squamous carcinogenesis. *Proc. Natl Acad. Sci. USA*, 108(26):10662-10667. [PMCID: PMC3127875](#)
71. Daldrup-Link H, Golovko D, DeNardo DG, Ruffell D, Castenada R, Wendland M, Corot C, **Coussens LM**. (2011) MR imaging of tumor-associated macrophages with clinically-applicable iron oxide nanoparticles. *Clin Can Res*. 17(17): 5695-5704. [PMCID: PMC3166957](#)
- Featured as journal cover image
72. Shiao S, Ganesan AP, Rugo HS, **Coussens LM**. (2011) Immune microenvironments in solid tumors: New targets for therapy. *Genes and Development*, 25(24): 2559-2572. [PMCID: PMC3248678](#)
73. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, **Coussens LM**. (2012) Leukocyte complexity in human breast cancer. *Proc. Natl Acad. Sci.*, 109(8):2796-2801. [PMCID: PMC3287000](#)
74. Ruffell B, Affara NI, **Coussens LM**. (2012) Differential macrophage programming in the tumor

- microenvironment. *Trends Immunol.* 33: 119-125. [PMCID: PMC3294003](#)
75. Hanahan D, **Coussens LM**. (2012) Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment, *Cancer Cell*, 21: 309-322. [PMID: 22439926](#)
- Reprinted as: 'Cell Press Supplement – Hallmarks of Cancer', April 2013. <http://onlinedigeditions.com/publication?i=151915>.
76. **Coussens LM**, Zitvogel L, Palucka AK. (2013) Neutralizing tumor-promoting chronic inflammation: A magic bullet? *Science*, 339 (117): 286-291. [PMCID: PMC3591506](#)
77. Ganessian AP, Johanson M, Ruffell B, Beltran A, Lau J, Jablons DM, **Coussens LM**. (2013) Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cells responses to lung adenocarcinoma. *J Immunology*, 191(4):2009-2017. [PMCID: PMC3774528](#)
78. Ruffell B, Affara NI, Cottone L, Junankar, S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogoyo M, **Coussens LM**. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. *Genes Dev.* 27(19): 2086-2098. [PMCID: PMC3850093](#)
- Featured as journal cover image
 - Research Highlight 'In Brief'; 'Tumor Microenvironment: Tissue-Specific Functions'; Nature Reviews Cancer 13, 757 (2013). By: Sarah Seton-Rogers
79. Strachan DC, Ruffell B, Oei Y, Bissell M, **Coussens LM**, Pryer N, Daniel D. (2013) CSF1R inhibition impedes turnover of tumor-associated macrophages and increases infiltration by antitumor CD8+ T cells in murine mammary and cervical carcinomas. *OncImmunology*, 1;2(12):e26968. [PMCID: PMC3902121](#)
80. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, rucki AA, Gunderson AJ, **Coussens LM**, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM. (2014) A listeria vaccine and depletion of T-regulatory cells activate immunity against early-stage pancreatic intra-epithelial neoplasms and prolong survival of mice. *Gastroenterology*, 146(7): 1784-1794. [PMCID: PMC4035450](#)
81. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Kulesz-Martin M, Irving B, **Coussens LM**. (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell*, 25(6): 809-821. [PMCID: PMC4063283](#)
82. Fornetti J, Mrtinson H, Betts CB, Lyons TR, Jindal S, Guo Q, **Coussens LM**, Borges VF, Schedin P. (2014) Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. *J Mammary Gland Biol Neoplasia* 2014 Jun 22. [Epub ahead of print]. [PMID: 24952477](#)
83. Medler TR, **Coussens LM**. (2014) Duality of the immune response in cancer: Lessons learned from skin. *J Invest Derm.* Special edition 'Milestones in Cutaneous Biology', in press.

Manuscripts Submitted or In Revision:

- Daldrup-Link, HE, Ansari C, Shaw A, Ito K, Hong SH, Sidani M, Hoffman M, Pisani L, Boudreau N, Gambhir SS, **Coussens LM**. Alk5-inhibition increases contrast agent delivery to tumors. *In revision*
- Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Rugo H, Pryer N, Daniel D, **Coussens LM**. Macrophages limit chemotherapeutic efficacy by repressing dendritic cell production of interleukin 12. *Submitted*.

IX. PATENTS

1. U.S. Patent Application Serial No. 10/567,873
Title: *Novel Indications for Transforming Growth Factor-Beta Regulators*.
Inventors: **Lisa M. Coussens** and Zena Werb
Application published on August 28, 2008 as U.S. Patent Publication #2008-0206219-A1
International filing date: August 9, 2004. Application Filing Number: 60/493,643; Docket Number: 23540-09361/PCT; International Publication Number WO 2005/013915 A2; International Application Number: PCT/US2004/025902
2. DeNardo D, Brennan D, **Coussens LM**. *Phenotyping Tumor-Infiltrating Leukocytes*. US patent publication No.: US 2014/0100188 A1, April 10, 2014; EP application: 10802804.4, AU application: 2010276324.

X. EDITORIALS, REVIEWS, and other NON-PEER REVIEWED PUBLICATIONS

Review Articles, Symposium Proceedings and Editorials

1. Ullrich A, Gray A, Berman C, **Coussens LM**, Dull T. (1983) Sequence homology of human and mouse Beta-nerve growth factor subunit genes. *CSHSQ* 48:435-442. [PMID: 6327169](#)
2. Ullrich A, Riedel H, Yarden Y, **Coussens LM**, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ. (1986) Protein kinases in cellular signal transduction: Tyrosine kinase growth factor receptors and protein kinase C. *CSHSQ* 51:713-724. [PMID: 3472757](#)
3. Chen E, **Coussens LM**, Liao Y-C, Smith D, Yang-Feng T, McGrath J, Van Beveren C, Verma IM, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. (1986) Structural features of growth factor receptors with oncogenic potential. *Biochem. Soc. Symp.* 52:65-82. [PMID: 3579970](#)
4. **Coussens LM**, Werb Z. (2001) Inflammatory cells and cancer: Think Different! *J. Exp. Med.* 193:F23-F26. [PMCID: PMC2193419](#)
5. Rhee JS, **Coussens LM**. (2002) RECKing MMP functions: Implications for cancer development. *Trends in Cell Biology*, 12: 209-211. [PMID: 12062160](#)
6. van Kempen LCL, **Coussens LM**. (2002) MMP9 potentiates pulmonary metastasis formation. *Cancer Cell*, 2: 251-252. [PMID: 12398887](#)
7. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian L, Sloane BF, Noel A, Hendrix MJ, **Coussens LM**, Padarathsingh M. (2004) Proteases, Extracellular Matrix and Cancer: A workshop of the PathB study section. *Am J Pathol*, 164:1131-1139. [PMCID: PMC1615345](#)
8. Balkwill F, **Coussens LM**. (2004) Inflammation and cancer – the missing link? *Nature* 431:405-406. [PMID: 15385993](#)
9. Robinson S, **Coussens LM**. (2005) Soluble mediators of inflammation during tumor development. *Adv Cancer Research* 93:159-187. [PMID: 15797447](#)
10. Fingleton B, **Coussens LM**. (2005) Host-tumor interactions influencing cancer progression. *Drug Discovery Today: Disease Mechanisms*, 2:199-204
11. De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, **Coussens LM**, Cohen MB. (2006) Tumor Progression and Metastasis from Genetic to Microenvironmental Determinants: A Workshop of the Tumor Progression and Metastasis NIH Study Section in Honor of Dr. Martin L. Padarathsingh, May 31, 2006, *Cancer Biol Ther.* 5:1588-1599. [PMID: 17224636](#)
12. **Coussens LM**. Inflammation, Proteolysis and Cancer Development. *In: Cancer Microenvironments. Extended Abstracts for the 37th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 2006.* (H Esumi, HL Moses, S Hirohashi, K Miyazono, ED). Princess Takamatsu Research Fund. Tokyo Japan, pp. 33-35.
13. Affara NI, **Coussens LM**. (2007) IKK α at the crossroads of inflammation and metastasis. *Cell*, 129: 25-26. [PMID: 17418780](#)
14. **Coussens LM**, Jacks T. (2008) Genetic and cellular mechanisms of oncogenesis. Editorial Overview. *Curr Opin Genet Dev*, 18:1-2. [PMID: 18440220](#)
15. DeNardo DG, Johansson M, **Coussens LM**. (2008) Inflaming gastrointestinal oncogenic programming. *Cancer Cell*, 14: 7-9. [PMID: 18598939](#)
16. Yahui-Beltran A, **Coussens LM**, Jablons DM. (2009) Respiratory homeostasis and exploitation of the immune system for lung cancer vaccines. *US Oncology*. 5(1):40-47. [PMID: 22368692](#)
17. Demaria S, Pikarsky E, Karin M, **Coussens LM**, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. (2010) Cancer and inflammation: promise for biologic therapy. *J Immunother.* 33(4):335-351. [PMCID: PMC2941912](#)
18. Ruffell B, **Coussens LM** (2011) Histamine restricts cancer: Nothing to sneeze at. *Nat Med* 17, 43-44. [PMCID: 2494984](#)
19. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, **Coussens LM**, DeClerck YA. (2012) Conference Report: Tumor microenvironment complexity: Emerging roles in cancer therapy. *Cancer Research*, 72(10):2473-2480. [PMCID: PMC3653596](#)
20. Daldrup-Link H. & **Coussens LM**. (2012) MR imaging of tumor-associated macrophages. *Oncol Immunology* 1(4), 507-509. [PMCID: PMC3591506](#)
21. Gunderson AG, **Coussens LM** (2013) B cells and their mediators as targets for therapy in solid tumors.

- Exp Cell Res.* 319, 1644-1649. [PMCID: PMC3743954](#)
22. Ruffell B, **Coussens LM** (2013) Some DCs are “B”etter. *Immunity* 38(4): 626-628. [PMID: 23601679](#)
23. Palucka K, **Coussens LM**, O’Shaughnessy (2013) Dendritic cells, inflammation and breast cancer. *Cancer J.* 19(6):511-516. [PMCID: 3886565](#)
24. Chan CJ, **Coussens LM** (2013) Poker face no more: cancer recurrence reveals its hand. *Nature Medicine*, 19(12):1569-1570. [PMID: 24309652](#)
25. Anand S, **Coussens LM** (2014) Manipulating micro RNAs to reverse macrophage polarization in glioma. *J Natl Can Inst., in press*

Book Chapters

1. Breakefield XO, Orloff G, Castiglione CM, Axelrod FB, **Coussens LM**, Ullrich A. (1983) Genetic linkage analysis in familial dysautonomia using a DNA probe for Beta-nerve growth factor. In: *Biochemical and Clinical Aspects of Neuropeptides: Synthesis Processing and Gene Structure* (Koch, G., Richter, D., Eds.) Academic Press, San Francisco, pp. 113-128.
2. Breakefield XO, Castiglione CM, **Coussens LM**, Axelrod FB, Ullrich A. (1984) Linkage analysis in familial dysautonomia using polymorphisms in DNA sequence: A beginning. In: *Cellular and Molecular Biology of Neuronal Development* (Black, I.B., Ed.) Plenum Press, New York, pp. 309-328.
3. Ullrich A, **Coussens LM**, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Whittle N, Waterfield MD. Seeburg PH (1985) Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells. In: *Cancer Cells 3: Growth Factors and Transformation*, Cold Spring Harbor Laboratory, New York, pp. 1-9.
4. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, **Coussens LM**, Liao Y-C, Tsubokawa M, Grunfield C, Rosen OM, Ramachandran J. (1986) Structure of the human insulin receptor precursor. In: *Mechanisms of Insulin Action* (Belfrage, P., Donner, J., and Stralfors, P., Eds) Elsevier Science Publishers (Biomedical Division), New York, pp. 1-11.
5. Riedel H, Yarden Y, **Coussens LM**, Lee J, Dull TJ, Gray A, Schlessinger J, Ullrich A. (1986) Structural and functional analysis of cell surface receptors with tyrosine kinase activity. In: *Cell Cycle and Oncogenes* (Tanner, W., and Gallwitz, D., Eds.) Springer Verlag, Heidelberg, pp. 157-171.
6. Werb Z, Vu TH, Rinkenberger JL, **Coussens LM**. (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. In: *Proteases and Protease Inhibitors in Cancer*. (L. Matrisian, N. Brunner, and K. Dano, Eds). *APMIS* 107:11-18. [PMID: 10190275](#)
7. Sternlicht MD, **Coussens LM**, Vu T, Werb Z. (2000) Biology and regulation of the matrix metalloproteinases. In: *Matrix Metalloproteinase Inhibitors in Cancer Therapy*. (NJ Clendeninn and K Apperlt, Eds). Humana Press, Totowa NJ, USA, pp. 1-38.
8. **Coussens LM**, Shapiro SD, Soloway PD, Werb Z. (2001) Models for gain-of-function and loss-of-function of MMPs: Transgenic and gene targeted mice. In: *Methods in Molecular Biology: Matrix Metalloproteinases*. (I. Clark, Ed.). Humana Press, Totowa, NJ, USA. pp. 149-179. [PMID: 11217297](#)
9. de Visser KE, **Coussens LM**. (2004) Inflammation and matrix metalloproteinases: Implications for cancer development. In: *Cancer and Inflammation*. (Morgan D, Forssman U, and Nakada M, Eds) Birkhauser Publishing, Basel, Switzerland. pp. 71-97.
10. Diaz RJ, Eichten AE, de Visser KE, **Coussens LM**. (2005) Matrix metalloproteinases: Mediators of Tumor-Host Cell Interactions. In: *Cancer Growth and Progression, Vol. 15. 2nd Edition* (Hans E. Kaiser, Series Ed), *Integration/Interaction of Oncologic Growth*, (Gary Meadows, Ed), Springer, The Netherlands. pp. 81-126.
11. Eichten A, Shen HCJ, **Coussens LM**. (2005) Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. In: *Current Protocols in Cytometry*, Unit 12.5, John Wiley & Sons, Inc., Canada. pp 12.5.1-12.5.11. [PMID: 18770816](#)
12. de Visser KE, **Coussens LM**. (2006) The inflammatory tumor microenvironment and its impact on cancer development. In: *Infection and Inflammation: Impacts on Oncogenesis* (T Dittmar, KS Zaenker, A Schmidt, Ed) Karger Pub. Basel Switzerland, vol 13, pp 118-137 [PMID: 16627962](#)
13. Eichten AE, de Visser KE, and **Coussens LM**. (2008) Macrophages in tumor development and metastasis. In: *Cancer Growth and Progression, 2nd Edition* (Hans E. Kaiser and Aejaz Nasir, Ed), *Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response*. (Ronald H. Goldfarb, Ed), Springer, The Netherlands. *Vol 11, pp115-137*.

14. De Palma M, **Coussens LM**. (2008) Immune cells and inflammatory mediators as regulators of tumor-associated angiogenesis. *In: Angiogenesis: an Integrative Approach from Science to Medicine* (W.D. Figg, J Folkman, Ed.) Springer Science, New York, NY USA, pp 225-238.
15. Affara NI, **Coussens LM**. (2008) Proteolytic pathways: Intersecting cascades in cancer development. *In: The Cancer Degradome-Proteases and Cancer Biology*, 1st Edition (Dylan Edwards, Gunilla Hoyer-Hansen, Francesco Blasi, Bonnie F. Sloane, Eds), Springer Science and Business Media, pp 157-182.
16. Affara NI, Andreu P, **Coussens LM**. (2009) Delineating protease function during cancer development. *In: Methods in Molecular Biology, Proteases and Cancer*. (Thomas Bugge and Toni Antalis, Eds.) Humana Press, 539:1-32. PMID: 19377975
17. de Visser KE, **Coussens LM**. (2011) Utilizing mouse models of human cancer for assessing immune modulation of cancer development. *In: Mouse Models for Cancer Research*. (Jeffrey Green and Thomas Ried, Eds.). Springer Science, Chapter 21, 443-463.
18. Kumar S, **Coussens LM**. Cancer microenvironments as therapeutic targets. *In: The cancer tissue microenvironment, Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. In press*
19. Chan C, **Coussens LM**. (2016) Inflammation and Cancer. *In: Encyclopedia of Immunobiology* (Michael J.H. Ratcliffe, Eds), Elsevier Limited. *In press*

Published Abstracts:

1. Laig-Webster M., **Coussens LM**, Caughey GH. (1998) A general method for genotyping mast cell-deficient KIT^W/KIT^{WV} mice by allele-specific polymerase chain reaction. *FASEB J*, 12:A895
2. McDonald DM, Thurston G, Murphy TJ, **Coussens L**, Baluk P. (1998) Wild-type FVB/N mice are unusually susceptible to *Mycoplasma pulmonis* respiratory tract infection. *FASEB J* 12(5) 4559 Part 2.
3. Baluk P, **Coussens LM**, Werb Z, Raymond WW, Caughey GH, McDonald DM. (1999) Gelatinase B is not essential for microvascular remodeling in airway inflammation. *Am. J. Resp. Crit. Care Med.* 159:A353
4. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2001) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Mol. Biol. Cell.* 12:269a.
5. van Kempen L, Rhee JS, Reuter J, Krane S, **Coussens LM**. (2002) To digest or not digest: Collagen Type I remodeling during squamous carcinogenesis. *Proceedings American Association for Cancer Research*, 43:535.
6. Chantrain C, Shimada H, **Coussens L**, Shalinsky D, Brekken J, De Clerck YA. (2002) Role of matrix metalloproteinase-2 and -9 in neuroblastoma angiogenesis and metastasis. *Proceedings American Association for Cancer Research*, 43:539.
7. Machamer JE, van Kempen LCL, **Coussens LM**. (2002) Endothelial cell migration through collagen is independent of collagenolysis. The International Symposium on Laboratory Automation and Robotics 2002, Boston, MA. Published online: <http://198.199.168.17:8080/islar/proceedings.nsf/>
8. van Kempen LCL, Lee J, Krane S, **Coussens LM**. (2002) Type I collagen remodeling functionally regulates vascular permeability and epithelial carcinogenesis. *Mol. Biol. Cell.* 13: 4a
9. Diaz RJ, van Kempen L, Dehne K, Schmuth M, Krane S, Albertson D, **Coussens LM**. (2004) Type I collagen remodeling regulates keratinocyte malignant potential. *Proceedings American Association for Cancer Research*, 45:792
10. de Visser KE, **Coussens LM**. (2004) The interplay between adaptive and innate immunity promotes cancer development. *Proceedings American Association for Cancer Research*, 45:403.
11. Eichten A, **Coussens LM**. (2004) Microenvironmental regulation of lymphatic metastasis development. *Proceedings American Association for Cancer Research*, 45:335.
12. **Coussens LM**. (2004) ECM architecture regulates tissue homeostasis and disease pathogenesis. *FASEB J*, 18:A21-A21.
13. **Coussens LM**. (2004) Inflammation and cancer. *Toxicologic Pathology*, 32:732.
14. Sharma S, Wesolowski R, Reebel L, Rodal MB, West B, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Rugo HS. (2014) A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and Paclitaxel in patients with advanced solid tumors. Am Soc Clin Onc, 2014. Abstract #134929
15. Rugo HS, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Karlin DA, Dowlati A, Le MH, **Coussens LM**, Wesolowski R. (2014) Phase 1b study of PLX3397, a CSF1R inhibitor, and paclitaxel in patients with advanced solid tumors. Eur Soc Med Onc 2014. Abstract #8457

